var title_f36_8_36992="SVC stents";
var content_f36_8_36992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Superior vena cava stenting for SVC syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The venogram shows tight stenosis of the superior vena cava (SVC) (black arrow). Flow in the markedly dilated azygos vein is reversed (white arrow) due to obstruction of the SVC. B) Venogram after stent placement: there is good flow in the SVC within the stent (between the arrows), and the azygos vein is no longer opacified due to normalization of flow towards the SVC.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dmitry Rabkin, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_36992=[""].join("\n");
var outline_f36_8_36992=null;
var title_f36_8_36993="T2 rectal cancer EUS";
var content_f36_8_36993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal cancer seen on endoscopic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image of a T2 rectal cancer with invasion of muscularis propria (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gavin C Harewood, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_36993=[""].join("\n");
var outline_f36_8_36993=null;
var title_f36_8_36994="Xanthogranulomatous PN Light";
var content_f36_8_36994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Xanthogranulomatous PN light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in xanthogranulomatous pyelonephritis showing an interstitial infiltrate composed of neutrophils, mononuclear cells, and, most characteristically, lipid-laden macrophages (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_36994=[""].join("\n");
var outline_f36_8_36994=null;
var title_f36_8_36995="Agenesis corpus callosum";
var content_f36_8_36995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Agenesis of the corpus callosum at 28 and 35 postmenstrual weeks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panels A and B, at 28 weeks showing the lateral ventricles (Lv) pointing up (Viking helmet) and in panel B the third ventricle (arrow) is displaced up coming all the way to the falx cerebri. Panel C, similar section to panel A. Panel D, a normal median section showing the normally developed corpus callosum for comparison. Panel E, a median section showing absence of the corpus callosum, abnormal gyral pattern (arrows) and a prominent third ventricle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_36995=[""].join("\n");
var outline_f36_8_36995=null;
var title_f36_8_36996="Difenoxin and atropine: Patient drug information";
var content_f36_8_36996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Difenoxin and atropine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33251?source=see_link\">",
"     see \"Difenoxin and atropine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Motofen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Difenoxin is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691226",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Atropine stops abuse of this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a child younger than 2 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to difenoxin, atropine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703489",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Loose stools caused by infection, fluid loss, very bad liver disease, or yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to take this drug as you have been told by your doctor. Do not use more than you were told to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12197 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_36996=[""].join("\n");
var outline_f36_8_36996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159875\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017416\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017415\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017420\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017421\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017423\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017418\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017419\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017424\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017425\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33251?source=related_link\">",
"      Difenoxin and atropine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_8_36997="Vorinostat: Patient drug information";
var content_f36_8_36997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vorinostat: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     see \"Vorinostat: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3362703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zolinza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8097314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zolinza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692073",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer from lymphoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vorinostat or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever and chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698041",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Extra muscle action.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia or low platelet count may rarely happen. This drug may need to be stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11906 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_36997=[""].join("\n");
var outline_f36_8_36997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362703\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097314\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030604\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030606\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030605\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030610\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030611\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030613\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030608\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030609\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030614\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030615\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=related_link\">",
"      Vorinostat: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_8_36998="Nadolol and bendroflumethiazide: Drug information";
var content_f36_8_36998=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nadolol and bendroflumethiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/18/18725?source=see_link\">",
"    see \"Nadolol and bendroflumethiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corzide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F198978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of hypertension:",
"     </b>",
"     Oral: Initial: Nadolol 40 mg and bendroflumethiazide 5 mg once daily. May increase dose to nadolol 80 mg and bendroflumethiazide 5 mg once daily if needed.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F198970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer dose every 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer dose every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer dose every 40-60 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Nadolol 40 mg and bendroflumethiazide 5 mg; nadolol 80 mg and bendroflumethiazide 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corzide&reg; 40/5: Nadolol 40 mg and bendroflumethiazide 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corzide&reg; 80/5: Nadolol 80 mg and bendroflumethiazide 5 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F198954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F198953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; combination product should not be used for initial therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bendroflumethiazide, sulfonamide-derived drugs, or any component of the formulation; bronchial asthma; sinus bradycardia; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur with bendroflumethiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating nadolol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms (eg, diaphoresis, tachycardia). May also reduce insulin secretion in response to hyperglycemia; adjustment of antidiabetic drugs may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by bendroflumethiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use nadolol with caution in patients with compensated heart failure and monitor for a worsening of the condition. Cardiac failure has occurred in patients without prior history; monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use bendroflumethiazide with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use bendroflumethiazide with caution in patients with hypokalemia; correct before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use nadolol with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use nadolol with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustments are required. May precipitate azotemia; discontinue or consider withholding if renal impairment occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Bendroflumethiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use nadolol with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal:",
"     <b>",
"      [U.S. Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia.",
"     </b>",
"     Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Used as a replacement for separate dosing of components or combination when response to single agent is suboptimal; the fixed combination is not indicated for initial treatment of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F198964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F198959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F198972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F198960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F198958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Corzide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-5 mg (100): $433.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-5 mg (100): $572.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nadolol-Bendroflumethiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-5 mg (100): $246.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-5 mg (100): $324.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6729947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess weight, fluid status; blood pressure, heart rate; serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Corgaretic (AE, JO, QA, SA);",
"     </li>",
"     <li>",
"      Corgaretic-40 (ZA);",
"     </li>",
"     <li>",
"      Corgaretic-80 (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F198956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Bendroflumethiazide: When used in this combination, bioavailability is increased 30% compared to single agent administration.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10192 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_36998=[""].join("\n");
var outline_f36_8_36998=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709162\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198978\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198969\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062282\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198970\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198952\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198942\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198954\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198953\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198976\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198957\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198944\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838220\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198948\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198964\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198950\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198959\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198972\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198960\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198958\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6729947\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539896\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198943\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198956\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10192\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10192|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/18/18725?source=related_link\">",
"      Nadolol and bendroflumethiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_8_36999="Management of bone metastases in advanced prostate cancer";
var content_f36_8_36999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of bone metastases in advanced prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     A Oliver Sartor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     Steven J DiBiase, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/36999/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/8/36999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19250910\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of prostate cancer at diagnosis have changed substantially since the introduction of prostate specific antigen (PSA) screening. Although a higher percentage of men have localized disease at presentation, metastatic prostate cancer remains an important clinical problem, in terms of the number of men with advanced disease, its impact on quality of life and as a cause of mortality.",
"   </p>",
"   <p>",
"    Osteoblastic lesions in bone are the most common site of metastasis. These frequently are symptomatic, and can cause pain, debility, and functional impairment. The treatment of bone metastases in men with prostate cancer is palliative. The goals of treatment are to improve survival, relieve pain, improve mobility, and prevent complications (eg, pathologic fractures, epidural spinal cord compression).",
"   </p>",
"   <p>",
"    The management of bone metastases in men with advanced prostate cancer is reviewed here. Treatment can include treatments directed specifically against the cancer involving bone, osteoclast inhibition to prevent complications from osseous involvement, and systemic therapy directed against the cancer.",
"   </p>",
"   <p>",
"    The clinical presentation and evaluation of bone metastases and the overall approach to the management of men with advanced prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41622?source=see_link\">",
"     \"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261306184\">",
"    <span class=\"h1\">",
"     TREATMENT SPECIFICALLY TARGETING BONE METASTASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261305501\">",
"    <span class=\"h2\">",
"     External beam radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiation therapy (RT) is the treatment of choice for men with castrate-resistant prostate cancer and bone pain that is limited to one or a limited number of sites. External beam RT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261305508\">",
"    <span class=\"h2\">",
"     Bone-targeted radiopharmaceuticals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with extensive multifocal painful bone metastases and those with persistent or recurrent pain despite receiving external beam RT to maximal normal tissue tolerance may achieve palliation of their symptoms by treatment with bone-targeted radioisotopes.",
"   </p>",
"   <p>",
"    A prerequisite for treatment with these radiopharmaceuticals is the presence of uptake on bone scan due to metastatic disease at the sites that correlate with pain. These radiopharmaceuticals are mainly used in men with advanced prostate cancer and symptomatic osteoblastic bone metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261306118\">",
"    <span class=\"h3\">",
"     Radium-223",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radium-223 (223Ra) is an alpha particle emitting radiopharmaceutical that has been evaluated in patients with castrate resistant prostate cancer and multiple symptomatic bone metastases. Radium is a bone-seeking element, and its decay allows the deposition of high energy radiation over a much shorter distance than with beta particle emitting radioisotopes, thus potentially treating tumor while minimizing toxicity to normal bone marrow.",
"   </p>",
"   <p>",
"    Radium-223 increased overall survival and reduced the incidence of serious skeletal-related events in the phase III ALSYMPCA trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In this trial, all patients had castration-resistant prostate cancer with multiple bone metastases and had either progressed on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    chemotherapy or were not candidates for docetaxel chemotherapy. Patients were required to have two or more bone metastases and no known visceral metastases.",
"   </p>",
"   <p>",
"    Overall, 921 patients were randomly assigned in a 2:1 ratio to radium-223 (one dose every four weeks for six cycles) or placebo. Approximately 80 percent had six or more lesions on bone scan and 40 percent had 20 or more lesions. Almost 60 percent had received prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    chemotherapy.",
"   </p>",
"   <p>",
"    Updated results were presented at the 2012 ASCO meeting and the 2013 ASCO GU symposium, based upon the entire study population of 921 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall survival was significantly prolonged with radium-223 compared with placebo (median 14.9 versus 11.3 months, HR 0.70, 95% CI 0.58-0.83). The survival benefit was consistent across all patient subgroups.",
"     </li>",
"     <li>",
"      Treatment with radium-223 was accompanied by a significant decrease in pain and opiate usage.",
"     </li>",
"     <li>",
"      The incidence of skeletal-related events was significantly decreased and the time to first skeletal-related event was significantly prolonged (median 15.6 versus 9.8 months, HR 0.66, 95% CI 0.52-0.83). The percentages of patients with spinal cord compression, pathologic bone fracture, or requiring external beam RT were significantly lower with radium-223 compared with placebo (4 versus 7 percent, 5 versus 7 percent, and 30 versus 34 percent, respectively).",
"     </li>",
"     <li>",
"      Treatment with radium-223 was well tolerated. There were only minimal increases in myelosuppression compared with placebo (grade 3 or 4 neutropenia 1.8 versus 0.8 percent, and grade 3 or 4 thrombocytopenia 6 versus 2 percent). Other clinically significant side effects were not increased compared with placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized trials that compare radium-223 with other agents known to prolong overall survival in patients with metastatic, castrate resistant prostate cancer (",
"    <a class=\"graphic graphic_table graphicRef53847 \" href=\"mobipreview.htm?19/23/19835\">",
"     table 1",
"    </a>",
"    ). The factors influencing the sequencing of different therapies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link&amp;anchor=H261299183#H261299183\">",
"     \"Overview of the treatment of disseminated prostate cancer\", section on 'Sequence of systemic therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radium-223 is currently available only through an expanded access protocol for patients who have symptomatic bone metastases and who are not candidates for, or refuse,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    chemotherapy (NCT01516762) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261305535\">",
"    <span class=\"h3\">",
"     Beta emitting radiopharmaceuticals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple beta-emitting radiopharmaceuticals have been evaluated and used clinically prior to the development of radium-223 (",
"    <a class=\"graphic graphic_table graphicRef53847 \" href=\"mobipreview.htm?19/23/19835\">",
"     table 1",
"    </a>",
"    ). The most widely studied have been samarium-153 and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26851?source=see_link\">",
"     strontium-89",
"    </a>",
"    . Other isotopes studied include phosphorus-32, rhenium-186, and rhenium-188 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials compared samarium-153 with placebo; these both found that treatment with samarium-153 was more effective than placebo in providing pain relief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Results from small randomized trials suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26851?source=see_link\">",
"     strontium-89",
"    </a>",
"    is as effective as external beam RT in providing pain relief and may decrease the incidence of new lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myelosuppression is the predominant toxicity associated with beta particle emitting radiopharmaceuticals and was more prominent with strontium than samarium. This toxicity has limited their usage, and there is no evidence that any of these radiopharmaceuticals prolongs survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1312968973\">",
"    <span class=\"h2\">",
"     Focused ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance guided focused ultrasound (ExAblate) is an approved device to provide palliation for painful bone metastases in patients who have either failed on standard RT or are not candidates for RT. The focused ultrasound waves raise the temperature at the imaged focal point and thus produce thermal tissue ablation. The regulatory approval of this device was based upon an international multicenter trial that demonstrated the activity and safety of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/15\">",
"     15",
"    </a>",
"    ], but the results of this trial have not been published in a peer reviewed journal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19250956\">",
"    <span class=\"h1\">",
"     OSTEOCLAST INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone metastases observed in prostate cancer are primarily osteoblastic, but there is a significant osteolytic component that is mediated by osteoclasts. Pathologic fractures do occur, although they are generally less frequent than in cancers with predominantly osteolytic disease. In addition, treatment with ADT can cause increased bone resorption and bone loss, which increases the risk of osteoporotic fractures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31737?source=see_link&amp;anchor=H19#H19\">",
"     \"Mechanisms of bone metastases\", section on 'Prostate cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteoclast inhibition using either a bisphosphonate or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    can help prevent the progression of bone metastases or the development of skeletal related complications and is recommended in patients with bone metastases from advanced prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19251243\">",
"    <span class=\"h2\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men with castrate-resistant prostate cancer and bone metastases, bisphosphonates slow the progression of skeletal-related events, which is a composite endpoint that includes pathologic fractures, radiation therapy [RT] to bone, surgery to bone, and spinal cord compression. Bisphosphonates also protect against the bone loss associated with androgen deprivation therapy (ADT). The FDA has approved only one bisphosphonate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , for use in castrate-resistant prostate with bone metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19251602\">",
"    <span class=\"h3\">",
"     Effect on progression of bone metastasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    on men with bone metastases has been studied in both castration resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] and castration sensitive prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in men with bone metastases and castration resistant prostate cancer was demonstrated in a trial in 643 men whose disease was progressing while on ADT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/19\">",
"     19",
"    </a>",
"    ]. Men were randomly assigned to one of two doses of zoledronic acid (4 mg or 8 mg) or placebo, each given every three weeks. The 8 mg dose of zoledronic acid was reduced to 4 mg early in the trial because of an increased risk of renal toxicity. At an average follow-up of 24 months, there was a significant reduction in the frequency of skeletal related events in men receiving zoledronic acid compared to placebo (38 versus 49 percent), and the median time to develop a skeletal related events was significantly longer with zoledronic acid (488 versus 321 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/16\">",
"     16",
"    </a>",
"    ]. Pain and analgesic scores were significantly higher in men who received placebo than in those who received zoledronic acid, but there were no differences in disease progression, performance status, or quality-of-life scores among the groups.",
"   </p>",
"   <p>",
"    In contrast, no benefit was demonstrated when treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    is initiated during initial treatment with ADT in men with bone metastases. In the CALGB 90202 trial, 645 men were randomly assigned to zoledronic acid or placebo. Preliminary results were presented at the 2013 ASCO GU symposium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/18\">",
"     18",
"    </a>",
"    ]. With a median follow-up of 24 months, there was no statistically significant difference in the time to first skeletal related event (median 32.5 versus 29.8 months, HR 0.96); overall survival also was not significantly different (hazard ratio 0.89; 95% CI 0.70-1.14).",
"   </p>",
"   <p>",
"    Other bisphosphonates are not equally effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. Trials with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    have yielded equivocal results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], and two trials with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    did not identify a statistically significant benefit in terms of skeletal related events or pain control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    is approved in the United States for use in men with castrate resistant prostate cancer and bone metastases. The European Committee for Proprietary Medicinal Products has approved zoledronic acid for all men with bone metastases from prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19251609\">",
"    <span class=\"h3\">",
"     Prevention of bone metastasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preclinical data suggest that bisphosphonates have an antitumor effect in prostate cancer, the adjuvant use of bisphosphonates in men with castrate-resistant prostate but without bone metastases has never been shown to significantly decrease the incidence of bone metastases.",
"   </p>",
"   <p>",
"    In the largest trial using adjuvant bisphosphonate therapy, 508 men with nonmetastatic androgen sensitive prostate cancer were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/25\">",
"     25",
"    </a>",
"    ]. There was no decrease in the incidence of bone metastases (80 events versus 68 events with placebo).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    has not been studied in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19251616\">",
"    <span class=\"h3\">",
"     Prevention of ADT-related bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates significantly decrease bone turnover and increase bone mineral density in men receiving androgen deprivation therapy (ADT) for prostate cancer. The results of randomized trials in this setting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H10#H10\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19251250\">",
"    <span class=\"h2\">",
"     Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a fully humanized monoclonal antibody that binds to the RANK ligand, a key factor in the pathway for osteoclast formation and activation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31737?source=see_link&amp;anchor=H10#H10\">",
"     \"Mechanisms of bone metastases\", section on 'RANKL and OPG'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    has been evaluated in a range of clinical settings. Denosumab is approved for the prevention of skeletal related events in men with prostate cancer bone and for the treatment of bone loss in men receiving ADT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19252106\">",
"    <span class=\"h3\">",
"     Prevention of skeletal related events",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in preventing skeletal related events in men with castrate resistant prostate cancer, although it does not improve overall survival or time to disease progression.",
"   </p>",
"   <p>",
"    In a double-blind phase III trial 1901 men with castrate-resistant prostate cancer and at least one bone metastasis were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    (120 mg) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (4 mg), each given every four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients on both treatment arms were advised to use calcium and vitamin D supplements. The primary objective of the study was time to first skeletal-related event (pathologic fracture, need for radiation therapy or surgery, or spinal cord compression).",
"   </p>",
"   <p>",
"    At a median follow-up of approximately 12 months, results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The time to first skeletal-related event was significantly delayed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (median 20.7 versus 17.1 months, HR 0.82, 95% CI 0.71-0.95).",
"     </li>",
"     <li>",
"      There was no statistically significant difference in either overall survival (19.4 versus 19.8 months, HR 1.03) or time to disease progression (8.4 months with both regimens, HR 1.06).",
"     </li>",
"     <li>",
"      Both treatments were well tolerated. Osteonecrosis of the jaw was more frequent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (2.3 versus 1.3 percent). Hypocalcemia was also significantly more frequent with denosumab (13 versus 6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19252367\">",
"    <span class=\"h3\">",
"     Prevention of bone metastasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    delays the time to first bone metastasis, it does not improve overall survival nor overall progression-free survival and is associated with osteonecrosis of the jaw in a significant number of cases. Denosumab is not been approved for this indication.",
"   </p>",
"   <p>",
"    In a phase III trial, 1432 men with non-metastatic castration-resistant prostate cancer were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/27\">",
"     27",
"    </a>",
"    ]. All patients either had undergone bilateral orchiectomy or had received continuous treatment with a gonadotropin releasing hormone agonist or antagonist for at least six months. Patients were castration-resistant, based upon three consecutive rising PSA determinations. Patients were classified as high risk for the development of bone metastases based upon a serum PSA &ge;8.0",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    or a PSA doubling time &lt;10 months.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    significantly increased the bone metastasis-free survival compared with placebo (29.5 versus 25.2 months, HR 0.85, 95% CI 0.73-0.98). A similar four month increase was observed in the time to first bone metastasis. However, there was no significant difference in overall survival (median 44 versus 45 months, HR 1.01).",
"   </p>",
"   <p>",
"    A subsequent analysis of this trial found that patients with a rapid PSA doubling had a shorter time to the development of bone metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/36999/abstract/28\">",
"     28",
"    </a>",
"    ]. Furthermore, the impact of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    in delaying the development of bone lesions was more pronounced. For patients with a PSA doubling time &le;6 months, the median time to bone metastases was 25.9 months with denosumab versus 18.7 months with placebo (HR 0.77, 95% CI 0.64-0.93).",
"   </p>",
"   <p>",
"    Osteonecrosis of the jaw was observed in 5 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    and was not observed with placebo. Hypocalcemia was more common with denosumab (1.7 versus 0.3 percent).",
"   </p>",
"   <p>",
"    The FDA assessed the possibility of approving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    for prevention of bone metastatic disease and rejected this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19252393\">",
"    <span class=\"h3\">",
"     Effect on ADT-induced osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    effectively increases bone density and prevents the development of osteoporosis-associated fractures caused by androgen deprivation therapy (ADT). &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2165876631\">",
"    <span class=\"h2\">",
"     Calcium and vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium and vitamin D levels should be assessed and low levels corrected prior to initiating therapy. If there are no contraindications (eg, preexisting hypercalcemia, recurrent renal stones), all patients receiving an osteoclast inhibitor should receive calcium and vitamin D&nbsp;supplementation to prevent secondary hyperparathyroidism and hypocalcemia and to ensure sufficient calcium for bone",
"    <span class=\"nowrap\">",
"     repair/healing.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19252098\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention and management of complications associated with osteoclast inhibitors (bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261304069\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic anticancer treatment is an important component of care for men with metastatic prostate cancer causing bone metastases. The use of androgen deprivation therapy as initial therapy and various other modalities for castrate resistant disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261304154\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of surgery or kyphoplasty for bone lesions in men with metastatic prostate cancer is generally reserved for patients with pathologic fractures or epidural spinal cord compression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261304161\">",
"    <span class=\"h1\">",
"     ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of pharmacologic agents are available to treat cancer-related bone pain that is not adequately controlled by measures specifically directed against the metastatic disease. Pain management in cancer patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=see_link\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19249949\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoblastic bone lesions in the axial skeleton are the most frequent site of metastasis in men with advanced prostate cancer. Treatment is palliative, with the goal of prolonging survival, relieving pain, improving mobility, and preventing complications such as pathologic fractures or epidural cord compression.",
"     </li>",
"     <li>",
"      Systemic therapy is an important component of patient management for controlling symptoms and slowing progression of bone metastases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link\">",
"       \"Overview of the treatment of disseminated prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients whose pain is not controlled with systemic therapy and who have either a single or limited number of focal symptomatic bone metastases, we recommend external beam radiation therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with castrate resistant prostate cancer and multifocal symptomatic osteoblastic bone metastases that are not controllable with systemic therapy or external beam RT, bone-targeting radiopharmaceuticals may offer significant palliative benefit (See",
"      <a class=\"local\" href=\"#H261305508\">",
"       'Bone-targeted radiopharmaceuticals'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Radium-223 is an alpha particle emitting agent that offers significant advantages because of its localized deposition of radiation. In a phase III trial, radium-223 improved overall survival and decreased skeletal-related events in men with advanced castrate resistant disease. Radium-223 currently is only available on compassionate use protocols. (See",
"      <a class=\"local\" href=\"#H261306118\">",
"       'Radium-223'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with castrate-resistant prostate cancer and bone metastases, we recommend an osteoclast inhibitor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      ) to reduce the risk of skeletal complications from progression of bone metastases (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For most patients, we suggest denosumab rather than zoledronic acid based upon its efficacy in a large randomized trial (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). For patients in whom cost",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reimbursement are important considerations, zoledronic acid is an appropriate alternative. (See",
"      <a class=\"local\" href=\"#H19251602\">",
"       'Effect on progression of bone metastasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19252106\">",
"       'Prevention of skeletal related events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of cancer-related bone pain that is not adequately controlled by measures specifically directed against the metastatic disease is an important component of overall patient management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=see_link\">",
"       \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link\">",
"       \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 30, 2012 (suppl; abstr LBA4512) .",
"    </li>",
"    <li>",
"     Sartor AO, Heinrich D, O'Sullivan JM, et al. Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). J Clin Oncol 30, 2012 (suppl; abstr 4551)",
"    </li>",
"    <li>",
"     Vogelzang, N, et al. Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). J Clin Oncol 2013;31 (suppl 6; abstr 11).",
"    </li>",
"    <li>",
"     Nilsson S, et al. Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2013; 31: (suppl 6; abstr 19).",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ (Accessed on July 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/6\">",
"      Roqu&eacute; M, Martinez MJ, Alonso P, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2003; :CD003347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/7\">",
"      Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007; 28:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/8\">",
"      Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/9\">",
"      Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/10\">",
"      Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/11\">",
"      Buchali K, Correns HJ, Schuerer M, et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988; 14:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/12\">",
"      Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/13\">",
"      Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/14\">",
"      Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44:519.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/cdrh_docs/pdf11/P110039b.pdf (Accessed on November 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/16\">",
"      Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/17\">",
"      Weinfurt KP, Anstrom KJ, Castel LD, et al. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 2006; 17:986.",
"     </a>",
"    </li>",
"    <li>",
"     Smith MR, Halabi S, Ryan CJ, et al. Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). J Clin Oncol 2013; 31: (suppl 6; abstr 27).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/19\">",
"      Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/20\">",
"      Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009; 6:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/21\">",
"      Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/22\">",
"      Rodrigues P, Hering F, Campagnari JC. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 2004; 7:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/23\">",
"      Hering F, Rodrigues PR, Lipay M. Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol 2003; 29:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/24\">",
"      Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21:4277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/25\">",
"      Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007; 99:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/26\">",
"      Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/36999/abstract/27\">",
"      Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379:39.",
"     </a>",
"    </li>",
"    <li>",
"     Saad F, Smith MR, Shore ND, et al. Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. J Clin Oncol 2012; 30: (suppl; abstr 4510).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17128 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_36999=[""].join("\n");
var outline_f36_8_36999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19249949\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19250910\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261306184\">",
"      TREATMENT SPECIFICALLY TARGETING BONE METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261305501\">",
"      External beam radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261305508\">",
"      Bone-targeted radiopharmaceuticals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261306118\">",
"      - Radium-223",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261305535\">",
"      - Beta emitting radiopharmaceuticals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1312968973\">",
"      Focused ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19250956\">",
"      OSTEOCLAST INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19251243\">",
"      Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19251602\">",
"      - Effect on progression of bone metastasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19251609\">",
"      - Prevention of bone metastasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19251616\">",
"      - Prevention of ADT-related bone loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19251250\">",
"      Denosumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19252106\">",
"      - Prevention of skeletal related events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19252367\">",
"      - Prevention of bone metastasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19252393\">",
"      - Effect on ADT-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2165876631\">",
"      Calcium and vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19252098\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261304069\">",
"      SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261304154\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261304161\">",
"      ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19249949\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/17128\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/17128|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/23/19835\" title=\"table 1\">",
"      Properties therap radionuclides",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41622?source=related_link\">",
"      Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31737?source=related_link\">",
"      Mechanisms of bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_8_37000="Pegylated interferon (peginterferon) alfa-2b and ribavirin: Drug information";
var content_f36_8_37000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2b and ribavirin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/5/37974?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pegetron&reg;;",
"     </li>",
"     <li>",
"      Pegetron&reg; RediPen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent;",
"     </li>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Canadian Consensus Guidelines recommend peginterferon plus ribavirin as treatment of choice for chronic hepatitis C (HCV) (Sherman, 2007).  American Association for the Study of Liver Diseases (AASLD) practice guidelines also recommend the use of boceprevir or telaprevir in combination with peginterferon plus ribavirin for chronic HCV patients with genotype 1 (Ghany, 2011). Administration of acetaminophen 30 minutes prior to therapy may help reduce fever and headache associated with peginterferon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic hepatitis C:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pegetron&reg; peginterferon alfa-2b component: SubQ: 1.5 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      and",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pegetron&reg; ribavirin component: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      HCV genotype 1 (treatment-naive):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;65 kg: 800 mg/day (two 200 mg capsules in the morning and two 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     66-80 kg: 1000 mg/day (two 200 mg capsules in the morning and three 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     81-105 kg: 1200 mg/day (three 200 mg capsules in the morning and three 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;105 kg: 1400 mg/day (three 200 mg capsules in the morning and four 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      HCV nongenotype 1 (treatment-naive):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;65 kg: 800 mg/day (two 200 mg capsules in the morning and two 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     66-85 kg: 1000 mg/day (two 200 mg capsules in the morning and three 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;85 kg: 1200 mg/day (three 200 mg capsules in the morning and three 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Retreatment (relapser or nonresponder): Any HCV genotype:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;65 kg: 800 mg/day (two 200 mg capsules in the morning and two 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     66-85 kg: 1000 mg/day (two 200 mg capsules in the morning and three 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     86-105 kg: 1200 mg/day (three 200 mg capsules in the morning and three 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;105 kg: 1400 mg/day (three 200 mg capsules in the morning and four 200 mg capsules in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Treatment duration:",
"      </i>",
"     </b>",
"     Canadian consensus guidelines (Sherman, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      HCV genotype 1:",
"     </i>",
"     Treatment recommended for 48 weeks or may consider extended therapy up to 72 weeks in slow responders; may reduce treatment to 24 weeks in patients achieving RVR at 4 weeks",
"     <b>",
"      and",
"     </b>",
"     without poor response predictors (eg, high viral load, advanced fibrosis, elderly); discontinue therapy in patients failing to achieve EVR at 12 weeks or with detectable HCV RNA at 24 weeks; retreatment for 48 weeks is required in patients who relapse after discontinuing abbreviated therapy (24 weeks).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      HCV genotypes 2,3:",
"     </i>",
"     Treatment recommended for 24 weeks; may consider abbreviated therapy (12 or 16 weeks) in patients with weight-based ribavirin dosing and RVR; if relapse occurs following abbreviated therapy, retreat for 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      HCV genotype 4,5, and 6:",
"     </i>",
"     Treatment recommended for 48 weeks; discontinue therapy in patients failing to achieve EVR at 12 weeks or with detectable HCV RNA at 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Relapsing or nonresponding patients (regardless of genotype):",
"     </i>",
"     Peginterferon/ribavirin therapy may be considered in patients that have relapsed or were nonresponsive to prior interferon monotherapy or interferon/ribavirin combination therapy; discontinue therapy if EVR not achieved after 12 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F207107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, use caution and monitor closely for signs/symptoms of toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Serum creatinine &gt;2 mg/dL: Permanently discontinue therapy in any patient.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F207108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment provided in manufacturer&rsquo;s labeling; however, limited data shows C",
"     <sub>",
"      max",
"     </sub>",
"     increases with increasing severity of hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Indirect bilirubin &gt;5 mg/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV genotype 1 (treatment-naive): Continue current peginterferon alfa-2b dose; decrease ribavirin dose by 200 mg/day if receiving &le;1200 mg/day or by 400 mg/day if receiving 1400 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV nongenotype 1 (treatment-naive): Continue current peginterferon alfa-2b dose; decrease ribavirin dose to 600 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relapser or nonresponder (any HCV genotype): Continue current peginterferon alfa-2b dose; decrease ribavirin dose by 200 mg/day if receiving &le;1000 mg/day or by 400 mg/day if receiving &ge;1200 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Direct bilirubin &gt;2.5 times ULN or indirect bilirubin &gt;4 mg/dL (for &gt;4 weeks): Permanently discontinue both peginterferon alfa-2b and ribavirin in any patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     AST/ALT 2 times baseline",
"     <b>",
"      and",
"     </b>",
"     &gt;10 times ULN: Permanently discontinue both peginterferon alfa-2b and ribavirin in any patient.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F207121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Recommendations (per manufacturer labeling - also refer to dosing in renal and hepatic impairment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hemoglobin:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV genotype 1 (treatment-naive):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL: Continue current peginterferon alfa-2b dose; decrease ribavirin dose by 200 mg/day if receiving &le;1200 mg/day or by 400 mg/day if receiving 1400 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin decrease &ge;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week; decrease ribavirin dose by 200 mg/day if receiving &le;1200 mg/day or by 400 mg/day if receiving 1400 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL",
"     <b>",
"      or",
"     </b>",
"     &lt;12 g/dL after ribavirin dose is decreased for 4 weeks and stable cardiac disease: Permanently discontinue both peginterferon alfa-2b and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV nongenotype 1 (treatment-naive):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL: Continue current peginterferon alfa-2b dose; decrease ribavirin dose to 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin decrease &ge;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose by one-half; decrease ribavirin dose to 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL",
"     <b>",
"      or",
"     </b>",
"     &lt;12 g/dL after ribavirin dose is decreased for 4 weeks and stable cardiac disease: Permanently discontinue both peginterferon alfa-2b and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relapser or nonresponder (any HCV genotype):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL: Continue current peginterferon alfa-2b dose; decrease ribavirin dose by 200 mg/day if receiving &le;1000 mg/day or by 400 mg/day if receiving &ge;1200 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin decrease &ge;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week; decrease ribavirin dose by 200 mg/day if receiving &le;1000 mg/day or by 400 mg/day if receiving &ge;1200 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL",
"     <b>",
"      or",
"     </b>",
"     &lt;12 g/dL after ribavirin dose is decreased for 4 weeks and stable cardiac disease: Permanently discontinue both peginterferon alfa-2b and ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      White blood cells:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV genotype 1 (treatment-naive) or relapser/nonresponder (any HCV genotype):  WBC &lt;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV nongenotype 1 (treatment-naive): WBC &lt;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Decrease peginterferon alfa2b-dose by one-half.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Any patient with WBC &lt;1.0 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Permanently discontinue peginterferon alfa-2b and ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neutrophils:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV genotype 1 (treatment-naive) or relapser/nonresponder (any HCV genotype):  Neutrophils &lt;0.75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV nongenotype 1 (treatment-naive): Neutrophils &lt;0.75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Decrease peginterferon alfa-2b dose by one-half.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Any patient with neutrophils &lt;0.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Permanently discontinue peginterferon alfa-2b and ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Platelets:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV genotype 1 (treatment-naive) or relapser/nonresponder (any HCV genotype):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelet count &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelet count &lt;25 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Permanently discontinue peginterferon alfa-2b and ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCV nongenotype 1 (treatment-naive):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelet count &lt;80 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Decrease peginterferon alfa-2b dose by one-half.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelet count &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Permanently discontinue peginterferon alfa-2b and ribavirin.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8012044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Combination package:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegetron&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule: Ribavirin 200 mg (56s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, powder for reconstitution: Peginterferon alfa-2b: 50 mcg [contains polysorbate 80 and sucrose; two single-dose vials with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegetron&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule: Ribavirin 200 mg (56s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, powder for reconstitution: Peginterferon alfa-2b: 80 mcg [contains polysorbate 80 and sucrose; two single-dose Redipens&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegetron&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule: Ribavirin 200 mg (56s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, powder for reconstitution: Peginterferon alfa-2b: 100 mcg [contains polysorbate 80 and sucrose; two single-dose Redipens&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegetron&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule: Ribavirin 200 mg (70s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, powder for reconstitution: Peginterferon alfa-2b: 120 mcg [contains polysorbate 80 and sucrose; two single-dose Redipens&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegetron&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule: Ribavirin 200 mg (84s, 98s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, powder for reconstitution: Peginterferon alfa-2b: 150 mcg [contains polysorbate 80 and sucrose; two single-dose vials with diluent or two single-dose Redipens&reg;]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination therapy for the treatment of chronic hepatitis C in patients with compensated liver disease,  including treatment-naive patients and those who have failed prior treatment with pegylated or nonpegylated interferon alpha and ribavirin combination therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (32% to 65%), headache (39% to 62%), rigors (43% to 48%), fever (32% to 46%), insomnia (21% to 40%), chills (22% to 39%), irritability (17% to 35%), depression (12% to 34%), dizziness (10% to 21%), impaired concentration (5% to 19%), anxiety (8% to 16%), pain (4% to 13%), emotional lability (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (17% to 45%), pruritus (13% to 29%), dry skin (8% to 26%), rash (9% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (24% to 43%), anorexia (9% to 35%), weight loss (7% to 30%), diarrhea (12% to 22%), appetite decreased (8% to 18%), vomiting (8% to 16%), abdominal pain (3% to 15%), right upper quadrant pain (7% to 12%), xerostomia (5% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (16% to 34%), hemolytic anemia (&lt;1% to 28%), neutropenia (2% to 26%; grade 4: &lt;1% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (5% to 59%), injection site inflammation (20% to 27%), injection site erythema (10% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (26% to 56%), arthralgia (16% to 34%), weakness (4% to 28%), musculoskeletal pain (&lt;1% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (10% to 27%), cough (14% to 19%), pharyngitis (11% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (2% to 27%), viral infection (10% to 15%), diaphoresis (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (2% to 10%), tachycardia (&lt;1% to 10%), flushing (1% to 5%), hyper/hypotension (1% to 5%), syncope (1% to 5%), palpitation (&lt;1% to 5%), peripheral edema (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation (1% to 10%), nervousness (&lt;1% to 10%), apathy (2% to 5%), malaise (2% to 5%), vertigo (2% to 5%), aggression (1% to 5%), migraine (1% to 5%), hyper/hypoesthesia (1% to 5%), tremor (1% to 5%), confusion (&lt;1% to 5%), somnolence (&lt;1% to 5%), memory impairment (2% to 4%), amnesia (2% to 3%), lethargy (&le;1% to 3%), anger (2%), crying (1% to 2%), restlessness (1% to 2%), sleep disturbances (&le;1% to 2%);",
"     <b>",
"      Note:",
"     </b>",
"     Life-threatening psychiatric events (suicidal ideation, suicide attempt, suicide [completed], psychosis including hallucinations and aggressive behavior) have been reported in up to 1.2% of patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema (2% to 5%), hair texture abnormal (2% to 5%), photosensitivity (2% to 5%), eczema (1% to 5%), rash (erythematous and maculopapular; &lt;1% to 5%), hyperhidrosis (2% to 3%), dermatitis (2%), cellulitis (&le;1%), cheilitis (&le;1%), psoriasis (&le;1%), scaling (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menorrhagia (5% to 10%), menstrual disorder (5% to 10%), thyroid abnormalities (hyper-/hypothyroidism; 1% to 10%), amenorrhea (2% to 5%), lacrimal gland disorder (2% to 5%), libido decreased (1% to 5%), hyperuricemia (1% to 2%), TSH increased (1%), dehydration (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (4% to 10%), constipation (3% to 10%), taste perversion (3% to 10%), flatulence (2% to 5%), glossitis (2% to 5%), loose stools (2% to 5%), stomatitis (including aphthous and ulcerative; 1% to 5%), bleeding gums (&lt;1% to 5%), GERD (1% to 2%), herpes labialis (1% to 2%), mouth ulcerations (1% to 2%), abdominal distension (1%), burning mouth (1%), gastritis (1%), stomach discomfort (1%), serum amylase increased (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Prostatitis (2% to 5%), erectile dysfunction (1%), polyuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (2% to 10%; grades 3 and 4: &lt;1% to 7%), thrombocytopenia (&lt;1% to 7%), lymphopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (1% to 5%), injection site rash (1% to 4%), injection site pruritus (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (2% to 10%), back pain (5% to 6%), hypertonia (2% to 5%), muscle spasms (2% to 5%), limb pain (3% to 4%), bone pain (1%), neck pain (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision blurred (2% to 10%), conjunctivitis (2% to 5%), eye pain (&lt;1% to 5%), dry eyes (2% to 3%), photophobia (&le;1%), retinal exudates (&le;1%), visual disturbances (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing impaired/loss (2% to 5%), otitis media (2% to 5%), tinnitus (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (8% to 10%), nonproductive cough (5% to 10%), exertional dyspnea (4% to 5%), respiratory disorder (2% to 5%), bronchitis (1% to 5%), nasal congestion (1% to 5%), sinusitis (1% to 5%), rhinorrhea (&lt;1% to 5%), pharyngolaryngeal pain (2% to 4%), epistaxis (2%), upper respiratory tract infection (&lt;1% to 2%), postnasal drip (1%), nasal dryness (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Fungal infection (2% to 5%), herpes simplex (2% to 5%), thirst (2% to 5%), lymphadenopathy (&lt;1% to 5%), night sweats (1% to 2%), sensitivity to temperature extremes (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening; reported with other interferon preparations and/or ribavirin): Anaphylaxis, angioedema, aplastic anemia, arrhythmia, arthritis (including rheumatoid), bacterial infection (including sepsis), bipolar disorder, cardiac ischemia, cardiomyopathy, cerebrovascular hemorrhage, cerebrovascular ischemia, colitis (ischemic, ulcerative), coma, diabetes mellitus, diabetic ketoacidosis, DVT, encephalopathy, erythema multiforme, facial palsy, hepatotoxic reactions, homicidal ideation, hypersensitivity reactions, injection site necrosis, lower respiratory tract infection, macular edema, MI, myositis, nephrotic syndrome, optic neuritis, pancreatitis, papilledema, parosmia, pericarditis, peripheral neuropathy, pneumonia, pneumonitis, pulmonary infiltrates, pure red cell aplasia, rectal bleeding, renal failure, renal insufficiency, restless leg syndrome, retinal hemorrhages, retinal artery or vein obstruction, retinopathy, rhabdomyolysis, sarcoidosis (including exacerbation), seizures, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Use of alfa interferons has been associated with rare cases of autoimmune diseases including vasculitis, systemic lupus erythematosus, thrombocytopenic purpura (idiopathic and thrombotic), and Vogt-Koyanagi-Harada syndrome; altered lipid metabolism (including hypercholesterolemia and hyperlipemia), and pulmonary hypertension",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to polyethylene glycol (PEG), interferons, ribavirin, or any component of the formulation; autoimmune hepatitis or history of autoimmune disease; decompensated liver disease; history of or pre-existing severe psychiatric disorder; uncontrolled thyroid dysfunction; epilepsy; severe renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); males with a pregnant female partner; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Anemia and severe cytopenias have has been observed in patients receiving the interferon/ribavirin combination. Rarely, aplastic anemia has been observed with peginterferon alfa-2b therapy. Use peginterferon alfa-2b with caution in patients with low peripheral blood counts or myelosuppression, including concurrent use of myelosuppressive therapy. Reduce dose with decreased neutrophil, platelet count, or hemoglobin and discontinue therapy if significant decreases in neutrophil (&lt;0.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L),  platelet counts (&lt;25 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L), or hemoglobin &lt;8.5 g/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebrovascular events (ischemic and hemorrhagic) have been observed in patients receiving peginterferon alfa-2b, including patients without risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: High-dose peginterferon alfa-2b has been associated with significant obtundation and coma, including cases of encephalopathy (usually elderly patients), and rarely seizures. May cause CNS depression (somnolence, fatigue), which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colitis: Serious cases of ischemic and ulcerative colitis have been observed within 12 weeks of initiation of peginterferon alfa-2b therapy; discontinue therapy in suspected/confirmed colitis; upon discontinuation of therapy, resolution of colitis is usually observed within 1-3 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dehydration: Maintain adequate hydration; hypotension associated with dehydration has been observed with use alfa interferons (including peginterferon alfa-2b); fluid replacement may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dental/periodontal disorders: Have been reported with ribavirin and interferon therapy; patients should be instructed to brush teeth twice daily and have regular dental exams.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Interferon therapy is associated with immune-mediated reactions including erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia: Hemolytic anemia is a significant toxicity, usually occurring within 1-4 weeks, and may worsen underlying cardiac disease; use caution and assess cardiac disease before initiation; avoid use in patients with history of significant or unstable cardiac disease. Patients with renal dysfunction and/or those &gt;50 years of age should be carefully assessed for development of anemia. If any deterioration in cardiovascular status occurs, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Rare cases of acute hypersensitivity (eg, anaphylaxis, angioedema, bronchoconstriction) have been observed with alfa-interferon therapy. Discontinue therapy immediately with signs of hypersensitivity and treat appropriately. Transient skin reactions may not warrant treatment interruption in the absence of more severe reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertriglyceridemia: New onset or aggravation of existing hypertriglyceridemia (sometimes severe) has been observed with use of peginterferon alfa-2b; monitor lipids with therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Ophthalmologic disorders (including retinal hemorrhages, cotton wool spots, and retinal artery or vein obstruction) have occurred rarely in patients using peginterferon alfa-2b. Ophthalmic examinations are recommended prior to therapy for all patients and periodically during therapy for patients at risk for retinopathy (eg, diabetes mellitus or hypertension). Patients presenting with ocular symptoms (eg, loss of visual acuity or vision field) at any time during therapy should receive a prompt ophthalmic examination. Consider discontinuation of therapy with new or worsening ophthalmologic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Otic effects: Hearing impairment and/or loss have been observed with use of peginterferon alfa-2b.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Has been reported with use; interrupt therapy for signs/symptoms of pancreatitis. Discontinue therapy in suspected/confirmed pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disease:",
"     <b>",
"      [Canadian Boxed Warning]: Alpha interferons cause or aggravate fatal or life-threatening autoimmune disorders.",
"     </b>",
"     Patients predisposed to developing autoimmune disorders may be at greater risk (use is contraindicated in patients with history of autoimmune disease). Monitor patients closely. Discontinue therapy for persistently severe or worsening symptoms. Symptom resolution generally occurs upon discontinuation of therapy in most cases, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use peginterferon alfa-2b with caution in patients with ischemic or thromboembolic cardiac disease, heart failure, hypertension or arrhythmias; avoid use in patients with severe cardiac disease within previous 6 months; discontinuation of therapy may be indicated with worsening cardiovascular status. Rarely, cardiomyopathy has been reported in patients without prior history of cardiac disease; cardiomyopathy may be reversible following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocrine disorders: Use peginterferon alfa-2b with caution in patients with endocrine disorders; hyper/hypothyroid have been observed (infrequently) with use of peginterferon alfa-2b; changes may or may not reverse with therapy discontinuation; obtain thyroid stimulating hormone (TSH) levels if symptomatic; avoid initiating therapy or discontinue existing therapy with uncontrolled TSH levels; diabetes mellitus and hyperglycemia have been observed with use; monitor glucose; dosage adjustments of antidiabetic therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use is contraindicated in patients with epilepsy.  Rarely, high-dose peginterferon alfa-2b has been associated with seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Use of ribavirin may be associated with increased uric acid levels (due to hemolysis); monitor for signs/symptoms of gout (particularly in predisposed patients).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemoglobinopathies: Avoid use in patients with hemoglobinopathies (eg, sickle-cell anemia, thalassemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use in decompensated hepatic disease is contraindicated; use with caution in patients with mild-to-moderate hepatic impairment; discontinue treatment with worsening hepatic function or signs/symptoms of hepatic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious disorders:",
"     <b>",
"      [Canadian Boxed Warning]: Alpha interferons cause or aggravate fatal or life-threatening infectious disorders.",
"     </b>",
"     Monitor patients closely. Discontinue therapy for persistently severe or worsening symptoms. Symptom resolution generally occurs upon discontinuation of therapy in most cases, but not all cases. Investigate the etiology of any persistent fever during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic disorders:",
"     <b>",
"      [Canadian Boxed Warning]: Alpha interferons cause or aggravate fatal or life-threatening ischemic disorders.",
"     </b>",
"     Monitor patients closely. Discontinue therapy for persistently severe or worsening symptoms. Symptom resolution generally occurs upon discontinuation of therapy in most cases, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders:",
"     <b>",
"      [Canadian Boxed Warning]: Life-threatening or fatal psychiatric adverse events (psychosis, aggressive behavior, severe depression, suicidal behavior/ideation and suicide) have been reported in patients with and without previous psychiatric symptoms. Additional CNS adverse effects (confusion, mental status changes) have also been reported. Use with extreme caution in patients with a history of pre-existing psychiatric disorders who report a history of severe depression.",
"     </b>",
"     Use in patients with pre-existing or a history of",
"     <b>",
"      severe",
"     </b>",
"     psychiatric disorders is contraindicated. Onset of psychiatric or CNS adverse effects (including clinical depression) warrants careful neuropsychiatric monitoring during and for 6 months following discontinuation of therapy. Discontinue use with worsening or persistent symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Exacerbation of disease has been observed with use of peginterferon alfa-2b. Use only if potential benefit outweighs risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Evaluate renal function prior to initiating therapy and monitor closely during therapy;  use peginterferon alfa-2b with caution in patients with renal impairment; use is contraindicated if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute; use in moderate renal impairment is not recommended; monitor for signs/symptoms of toxicity (dosage adjustment required if toxicity occurs); discontinue therapy if serum creatinine  &gt;2 mg/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Avoid use in patients with chronic obstructive pulmonary disease (COPD); use caution in other pulmonary disease. Pulmonary effects (eg, pneumonitis, pulmonary infiltrates, pulmonary hypertension ), sometimes fatal, have been reported.  Symptomatic patients should receive a chest x-ray; if pulmonary abnormalities are present, monitor patient closely. Discontinuation of therapy may be necessary.  Concomitant use of the herbal product Shosaikoto has been associated with increased reports of pulmonary symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sarcoidosis: Exacerbation of disease has been observed with use of peginterferon alfa-2b. Use only if potential benefit outweighs risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medications causing lactic acidosis: Use with caution in patient receiving medications which may cause lactic acidosis (eg, nucleoside analogues).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Avoid use in patients with severe debilitating medical conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients; encephalopathy may be increased in the elderly as well as a higher frequency of anemia in older adults &gt;50 years of age and/or those with renal impairment &lt;50 mL/minute; monitor closely for anemia, particularly in the initial 4 weeks of therapy; evaluate renal function before initiating and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Use during pregnancy is contraindicated; avoid pregnancy in female patients and female partners of male patients during ribavirin therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy. If patient or female partner becomes pregnant during treatment, she should be counseled about potential risks of exposure. Manufacturer recommends reporting pregnancies to (800) 463-5442. Negative pregnancy test is required before initiation and monthly thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product variability:",
"     <b>",
"      Due to differences in dosage, patients should not change brands of interferons.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Safety and efficacy have not been established in patients who have received organ transplants, have been coinfected with HIV or hepatitis B. Ribavirin monotherapy is not effective and must be used in combination with interferon.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F207116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Ribavirin may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased.  Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients extra closely for signs/symptoms of myelosuppression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: Peginterferon Alfa-2b may decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: Peginterferon Alfa-2b may decrease the serum concentration of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Betaxolol (Ophthalmic); Carteolol (Ophthalmic); Timolol (Ophthalmic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Ribavirin may enhance the adverse/toxic effect of Didanosine. Ribavirin may increase serum concentrations of the active metabolite(s) of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons (Alfa): May enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Interferons (Alfa) may increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2b.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Nucleoside): Ribavirin may enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telbivudine: Peginterferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: May enhance the adverse/toxic effect of Ribavirin. Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin.  Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F207095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use during pregnancy is contraindicated. Abortifacient and/or teratogenic effects have been reported in animal studies with  interferons and ribavirin. Women of childbearing potential should not be treated unless two reliable forms of contraception are used. In addition, male patients and their female partners must also use two reliable forms of contraception. Pregnancy must be avoided during treatment and for 6 months following therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F207096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take oral formulation without regard to meals, but always in a consistent manner with respect to food intake (ie, always take with food or always take on an empty stomach).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC (pretreatment, at weeks 2 and 4 [or more frequently if indicated], and routinely during therapy) , renal and liver function tests (pretreatment and routinely during therapy), lipids, TSH, and electrolytes; glucose (diabetic or symptomatic patients); uric acid (patients predisposed to gout);  ECG (at baseline and during therapy) in patients with pre-existing cardiac disease; pretreatment and monthly pregnancy test for women of childbearing age; dental exams; neuropsychiatric monitoring during and for 6 months after discontinuing therapy (patients developing psychiatric or CNS problems); vision and hearing evaluations",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Serum HCV RNA levels (pretreatment, 4-,12-, and 24 weeks after therapy initiation, 24 weeks after completion of therapy)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F207089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Canadian consensus guidelines (Sherman, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rapid virological response (RVR): HCV RNA negative (&lt;50 units/mL) after 4 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Early virological response (EVR):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Early virological clearance (EVC): HCV RNA negative (&lt;50 units/mL) after 12 weeks of treatment",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Partial virological response (PVR): &ge;2-log decrease in HCV RNA but still positive for HCV RNA after 12 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sustained virological response (SVR): Absence of HCV RNA in the serum 6 months following completion of full treatment course",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F207097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pegatron Combination Therapy (NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peginterferon Alfa-2b: Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ribavirin: Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berg T, Von Wagner M, Nasser S, et al, &ldquo;Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(4):1086-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/8/37000/abstract-text/16618403/pubmed\" id=\"16618403\" target=\"_blank\">",
"        16618403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(1):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/8/37000/abstract-text/16401485/pubmed\" id=\"16401485\" target=\"_blank\">",
"        16401485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Nelson DR, Strader DB, et al, &ldquo;An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection:  2011 Practice Guideline by the American Association for the Study of Liver Diseases,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(4):1433-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/8/37000/abstract-text/21898493/pubmed\" id=\"21898493\" target=\"_blank\">",
"        21898493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management And Treatment Of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/8/37000/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoofnagle JH and Seeff LB,&rdquo;Peginterferon and Ribavirin for Chronic Hepatitis C,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(23):2444-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/8/37000/abstract-text/17151366/pubmed\" id=\"17151366\" target=\"_blank\">",
"        17151366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearlman BL, Ehleben C, and Saifee S, &ldquo;Treatment Extension to 72 Weeks of Peginterferon and Ribavirin in Hepatitis C Genotype 1-Infected Slow Responders,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2007, 46(6):1688-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/8/37000/abstract-text/18046717/pubmed\" id=\"18046717\" target=\"_blank\">",
"        18046717",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sherman M, Shafran S, Burak K, et al, &ldquo;Management of Chronic Hepatitis C: Consensus Guidelines,&rdquo;",
"      <i>",
"       Can J Gastroenterology",
"      </i>",
"      , 2007, 21(Suppl C):25-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/8/37000/abstract-text/17568823/pubmed\" id=\"17568823\" target=\"_blank\">",
"        17568823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strader DB, Wright T, and Thomas DL, et al, &ldquo;Diagnosis, Management And Treatment Of Hepatitis. American Association for the Study of Liver Diseases,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2004, 39(4):1147-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/8/37000/abstract-text/15057920/pubmed\" id=\"15057920\" target=\"_blank\">",
"        15057920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10256 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_37000=[""].join("\n");
var outline_f36_8_37000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207103\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207120\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207106\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062248\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207107\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207108\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207121\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012044\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234133\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207091\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207090\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207118\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207094\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207078\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207116\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207082\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207095\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207111\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207096\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207085\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207089\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207097\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207077\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207093\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10256\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10256|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/5/37974?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_8_37001="Cerebral amyloid angiopathy";
var content_f36_8_37001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cerebral amyloid angiopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/37001/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/37001/contributors\">",
"     Steven M Greenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/37001/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/37001/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/37001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/37001/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/8/37001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral amyloid angiopathy (CAA), although usually asymptomatic, is an important cause of primary lobar intracerebral hemorrhage in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It can occur as a sporadic disorder, sometimes in association with Alzheimer disease (AD), or as a certain familial syndrome. CAA is characterized by the deposition of congophilic material in small to medium-sized blood vessels of the brain and leptomeninges. In its most severe stages, the amyloid deposits cause breakdown of the blood vessel wall with resultant hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cerebral amyloid angiopathy (CAA), like Alzheimer disease (AD), is strongly age dependent. Based upon a series of 784 autopsy cases, we estimated the prevalence of moderate to severe CAA as 2.3 percent for patients between the ages of 65 and 74, 8.0 percent between the ages of 75 and 84, and 12.1 percent over the age of 85 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/3\">",
"     3",
"    </a>",
"    ]. Although sporadic, CAA-related symptoms are uncommon at ages younger than 60 to 65 they can more rarely affect individuals in their 50s as well.",
"   </p>",
"   <p>",
"    There is no strong predilection for gender. Although the association of CAA with hypertension is debated, it is clear that many patients with CAA-related hemorrhage are normotensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular amyloid deposits in sporadic cerebral amyloid angiopathy (CAA) are biochemically similar to the material comprising senile plaques in Alzheimer disease (AD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/1\">",
"     1",
"    </a>",
"    ]. The primary constituent of each is amyloid beta-peptide, a 39 to 43 amino acid fragment of the amyloid precursor protein. There is essentially no clinical overlap between CAA and the non-CNS systemic amyloidoses, such as primary (amyloid AL) and secondary (amyloid AA) amyloidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mutant amyloid precursor protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the gene that encodes the amyloid precursor protein (APP) are responsible for some cases of \"presenile\" CAA. While most of these mutations are also associated with at least some of the neuropathologic features of AD, at least one APP mutation (Leu34Val) has been reported to cause autosomal dominant CAA without parenchymal amyloid plaques or neurofibrillary tangles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is in-vitro evidence that the Dutch, Iowa, Italian, and Arctic mutations in APP may increase the toxicity of the peptide towards components of the vessel wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Another potentially pathogenic effect of these mutations is to decrease the susceptibility of the amyloid beta peptide to proteolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/10\">",
"     10",
"    </a>",
"    ] or clearance from the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/11\">",
"     11",
"    </a>",
"    ]. These findings highlight various mechanisms by which mutant APP might contribute to CAA in heritable forms of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Apolipoprotein E",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that initiate or promote amyloid beta-peptide deposition in CAA that occurs later in life are not well understood. However, a number of observations have begun to enhance our understanding of this disorder. Perhaps best studied has been the relationship between CAA and alleles of apolipoprotein E (APOE). Patients carrying the APOE epsilon 2 (&epsilon;2) or epsilon 4 (&epsilon;4) alleles appear to be at greater risk for CAA-related hemorrhage than those with only the common APOE epsilon 3 (&epsilon;3) allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/12-18\">",
"     12-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from a prospective cohort indicate that one or both of these alleles are present in approximately two-thirds of patients with CAA compared with only about one-quarter of elderly controls without hemorrhage. These alleles are associated with an increased likelihood of having a CAA-related hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], earlier age of disease onset (mean age of first hemorrhage 75 versus 82 years in patients who are not carriers of APOE &epsilon;2 or &epsilon;4), and a greater risk of hemorrhage recurrence (two year cumulative recurrence rate of 28 percent in carriers of &epsilon;2 or &epsilon;4 versus 10 percent for the APOE",
"    <span class=\"nowrap\">",
"     &epsilon;3/&epsilon;3",
"    </span>",
"    genotype) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients with CAA who have both APOE &epsilon;2 and &epsilon;4 alleles appear to have a particularly early onset of disease and a high risk of early recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. Carriers of the APOE &epsilon;2 allele also have larger ICH volumes, increased mortality, and worse functional outcomes compared to noncarriers, while these associations are not seen for carriers of the APOE &epsilon;4 allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from a population-based, case-control study suggest that the risk of lobar ICH associated with APOE alleles may be modified by variation elsewhere in the APOE gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/21\">",
"     21",
"    </a>",
"    ]. Notably, overall APOE haplotype (combination of multiple alleles on one chromosome) was also independently associated with lobar ICH, suggesting the presence of regulatory variants that could influence the effect of APOE &epsilon;2 or &epsilon;4 on the risk of lobar ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that interact with the &epsilon;2 genotype may promote cerebral hemorrhage. In one report, antiplatelet or anticoagulant medication, hypertension, or minor head trauma were significantly more common antecedents of CAA-related hemorrhage among &epsilon;2 carriers than among non-&epsilon;2 carriers (81 versus 35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/23\">",
"     23",
"    </a>",
"    ]. The authors hypothesized that this may result from an APOE isoform-specific effect upon amyloid laden blood vessels that causes the vessels to be more vulnerable to rupture in the presence of these other factors.",
"   </p>",
"   <p>",
"    Vascular rupture and bleeding in CAA appears to be a multistep process involving the deposition of amyloid beta-peptide in the vascular wall and subsequent vascular changes such as cracking of the vascular wall. It has been suggested that the &epsilon;2 and &epsilon;4 alleles act via separate mechanisms: &epsilon;4 increased amyloid beta-peptide deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/24\">",
"     24",
"    </a>",
"    ]; and &epsilon;2 causes amyloid-laden vessels to undergo changes such as cracking and necrosis that predispose to rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/15,25\">",
"     15,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is additional evidence that APOE &epsilon;4 alleles affect amyloid beta-peptide deposition. Among patients with severe head injury, for example, the APOE &epsilon;4 allele is associated with an increased risk of deposition of amyloid beta-peptide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/26\">",
"     26",
"    </a>",
"    ]. This allele also promotes deposition of amyloid beta-peptide in AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other molecular factors likely contribute to the pathogenesis of CAA. As an example, transgenic mice overexpressing the inflammatory cytokine transforming growth factor (TGF) beta-1 show increased amyloid beta-peptide deposition in cerebral blood vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/27\">",
"     27",
"    </a>",
"    ]. This finding may be applicable to humans, since postmortem studies have found that TGF beta-1 mRNA levels correlate strongly with amyloid beta-peptide deposition in damaged blood vessels in patients with CAA.",
"   </p>",
"   <p>",
"    A case-control genetic association study that included a prospective followup of 178 ICH survivors found that a variant within the CR1 gene (rs6656401) influences the risk and recurrence of CAA-related ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/28\">",
"     28",
"    </a>",
"    ]. In the same report, this genetic variant was also associated with the severity of vascular amyloid deposition on pathologic examination of 544 autopsy studies from two community-based clinical-pathological studies of aging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL AND RADIOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intracerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical manifestation of cerebral amyloid angiopathy (CAA) is spontaneous lobar hemorrhage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50480 \" href=\"mobipreview.htm?19/37/20051\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/29\">",
"     29",
"    </a>",
"    ] The term lobar refers to location in the cortex and subcortical white matter; this site is in contrast to the deep locations characteristic of hypertensive hemorrhage such as putamen, thalamus, and pons. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .) CAA-related hemorrhages often extend into the subarachnoid space, and less frequently rupture into ventricles.",
"   </p>",
"   <p>",
"    CAA-related hemorrhages have a predilection to cluster in posterior brain regions, and display an additional tendency to cluster in the same lobe within individual patients. Evidence for this comes from analysis of the spatial distribution of 321 intracerebral hemorrhages on gradient echo MRI in 59 patients with probable CAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/30\">",
"     30",
"    </a>",
"    ]. Hemorrhages were significantly more likely to occur in the temporal and occipital than the frontal and parietal lobes (ratio of actual to expected hemorrhages 1.37, 1.43, 0.58, and 1.0, respectively). In addition, prospective follow-up revealed that hemorrhages tended to recur in areas of prior hemorrhage regardless of lobe.",
"   </p>",
"   <p>",
"    The lobar location of the hemorrhages reflects the underlying distribution of the vascular amyloid deposits, which favor cortical vessels and largely spare white matter, deep gray matter, and the brainstem. The explanation for the posterior brain clustering of CAA hemorrhages is undetermined, but it may be related to as yet unknown characteristics of posterior circulation vessels that influence beta amyloid peptide elimination, or to increased vulnerability of these brain regions to minor trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cerebellum contains variable amounts of vascular amyloid and may be a site of CAA-related hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite extensive pathologic involvement of the leptomeningeal vessels, primary subarachnoid hemorrhage related to CAA is rare; however, superficial CAA-related bleeding can often be identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Hemosiderosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical presentation of CAA-related hemorrhage varies with the lesion's size and location. Large lobar hemorrhages, particularly those extending towards the ventricles, can cause hemiplegia and depressed consciousness; in comparison, smaller lobar hemorrhages can cause more limited focal deficits, seizure, or headache. Tiny asymptomatic hemorrhages appear to be common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its role in spontaneous hemorrhage, CAA underlies a substantial proportion of hemorrhages related to thrombolytic or anticoagulant agents. In a series of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -related lobar hemorrhages, for example, advanced CAA was present in 7 of 11 patients with available pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/36\">",
"     36",
"    </a>",
"    ]. Similarly, the TIMI II trial evaluating the use of tissue-type plasminogen activator for acute myocardial infarction identified severe CAA at postmortem examination in two of five patients with intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/37\">",
"     37",
"    </a>",
"    ]. The importance of CAA may contribute to the age-dependence of these medication-induced hemorrhages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Microhemorrhages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients present with incidental findings on MRI that suggest subclinical CAA. Neuroimaging data suggest that small subclinical leaks of blood called cerebral microhemorrhages (also known as microbleeds) are relatively common in CAA. Gradient echo or T2*-weighted MRI can detect these remnants of hemorrhage as 2 to 10 mm focal or multifocal areas of hemosiderin deposition. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Gradient-echo MRI'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In population-based studies, cerebral microhemorrhages are detected in 5 to 23 percent of older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. The underlying age of the population studied and the sensitivity of the MRI techniques used probably account for some of the variability in the observed prevalences. Most microhemorrhages (nearly three-quarters in the Framingham study) are in the cerebral cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/40\">",
"     40",
"    </a>",
"    ]. This location suggests CAA rather than hypertensive microangiopathy which primarily involves the basal ganglia, thalamus, or pons. The association between lobar microhemorrhages and APOE &epsilon;4 in the Rotterdam and other studies support the hypothesis that these lesions originate from CAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/18,43,44\">",
"     18,43,44",
"    </a>",
"    ]. Imaging studies have also associated the presence and distribution of microbleeds with concentrated amyloid deposition as seen on positron emission tomography using the amyloid ligand, Pittsburgh compound B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Rotterdam cohort, microbleeds were also more prevalent among those using antiplatelet agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/47\">",
"     47",
"    </a>",
"    ]. In another case series, microbleeds were also found to be more common in patients with ICH associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use compared to those with ICH who did not use aspirin and compared to aspirin users without ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings in one report suggest that microhemorrhages arise from an amyloid-based pathology that is in some respects distinct from that of macrohemorrhages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/49\">",
"     49",
"    </a>",
"    ]. Analysis of neuroimaging studies of 46 consecutive patients with CAA demonstrated a bimodal, rather than continuous, distribution of hemorrhage volumes. In a subset of patients who underwent autopsy, those with a large number of microbleeds had amyloid-positive vessels with thicker walls compared to those with a lower proportion of, or no microbleeds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transient neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A less common, but clinically important manifestation of CAA is transient neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/50\">",
"     50",
"    </a>",
"    ]. Affected patients complain of recurrent, brief (minutes), often stereotyped spells of weakness, numbness, paresthesias, or other cortical symptoms that can spread smoothly over contiguous body parts. These episodes may reflect abnormal activity (either focal seizure or spreading depression) of the surrounding cortex in response to the small hemorrhages. The anecdotal observation that anticonvulsants may stop the attacks is consistent with this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features that help distinguish these spells from true transient ischemic attacks include the smooth spread of the symptoms, the absence of hemodynamically significant stenosis in the relevant vascular supply, and the presence of small hemorrhage in the corresponding region of cortex (best shown with gradient-echo MRI; see below). Avoiding misdiagnosis is critical since the administration of anticoagulants for a presumed TIA can increase the risk of hemorrhagic stroke from CAA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Perivascular/vascular inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAA-related perivascular inflammation appears to represent a distinct subset of CAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The clinical presentation is that of acute or subacute cognitive decline rather than hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Seizures, headache, and focal neurologic signs are common. Neuroimaging shows a potentially reversible leukoencephalopathy consisting of patchy or confluent white matter hyperintensities on T2 weighted MRI sequences; multiple microhemorrhages are seen on gradient echo sequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55227 \" href=\"mobipreview.htm?28/27/29111\">",
"     image 2",
"    </a>",
"    ). Angiography or MRA does not show evidence of vasculitis. Neuropathology shows perivascular inflammation with multinucleated giant cells that is associated with amyloid laden vessels. ESR and C-reactive protein are commonly normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/54\">",
"     54",
"    </a>",
"    ]. Cerebrospinal fluid analysis may be normal, but often shows a pleocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mildly elevated protein.",
"   </p>",
"   <p>",
"    Clinical and radiographic improvement may occur with immunosuppressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/51,52,54,55\">",
"     51,52,54,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Immunosuppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The syndrome of CAA-related perivascular inflammation appears to be closely linked to the reported Abeta-related angiitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. These two inflammatory syndromes, distinguished by the presence or absence of true vasculitis on neuropathological examination, appear to share similar clinical presentations, imaging properties, and response to treatment. In two cases, patients with CAA-related inflammation were found to have autoreactive Abeta 1-42 antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/58\">",
"     58",
"    </a>",
"    ]. The Abeta-related secondary vasculitis also resembles primary CNS vasculitis in its clinical presentation and response to immunosuppressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced CAA is associated with cognitive impairment. An autopsy series found that moderate to severe CAA (present in 19 percent of the study population) was associated with impairments of perceptual speed and episodic memory, independently of age, sex, education, AD pathology, and other potential covariates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise mechanism by which advanced CAA contributes to cognitive impairment remains unknown. Some patients with extensive CAA present with progressive dementia along with ischemic white matter damage that is similar to patients with hypertensive vasculopathy and subcortical vascular dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/50,60,61\">",
"     50,60,61",
"    </a>",
"    ]. Other studies have correlated the number and presence of microbleeds in both population or hospital-based subjects with cognitive impairment and dementia, raising the possibility that these lesions are contributors to neurologic dysfunction, as well as markers of small vessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\", section on 'White matter lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\", section on 'Cerebral amyloid angiopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another potential mechanism for CAA-related cognitive dysfunction is infarction. One MRI study demonstrated a relatively high prevalence (15 percent) of clinically silent subacute cerebral infarcts in patients with CAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/64\">",
"     64",
"    </a>",
"    ]. The presence of these lesions was associated with the hemorrhage burden, but not with conventional atherosclerotic risk factors, suggesting that the pathogenesis is related to CAA rather than to comorbid ischemic cerebrovascular disease.",
"   </p>",
"   <p>",
"    CAA is also particularly common in conjunction with AD, appearing in moderate to severe form in 30 of 117 (26 percent) AD brains in an autopsy series; CAA with hemorrhage occurred in six (5.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/59,65\">",
"     59,65",
"    </a>",
"    ]. Another autopsy study found that patients with both CAA and AD had more severe cognitive impairment than patients with AD alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/66\">",
"     66",
"    </a>",
"    ]. Similarly, an MRI study in AD patients found that the presence of multiple microbleeds was associated with worse cognitive performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lobar hemorrhage in general is associated with features that are both favorable &mdash; their superficial location and tendency to spare the ventricles (and unfavorable to outcome), older age, and somewhat larger hematoma size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/12,68,69\">",
"     12,68,69",
"    </a>",
"    ]. Overall mortality in lobar hemorrhage due to CAA is in the range of 10 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], with the best prognosis for patients with smaller hematomas (&lt;50 mL) and greater level of consciousness on admission (Glasgow coma scale &ge;8).",
"   </p>",
"   <p>",
"    Although the acute outcome may be somewhat better in CAA-associated than in hypertensive hemorrhage, CAA carries a substantially higher risk of hemorrhage recurrence. A cohort of 71 consecutive survivors of lobar hemorrhage had a two year cumulative recurrence rate of 21 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/19\">",
"     19",
"    </a>",
"    ]. All but one of the recurrent hemorrhages were lobar, typically in a different location from the index hemorrhage. Age, sex, and hypertension did not predict recurrence, while those patients with history of hemorrhage prior to study entry were at approximately six times the risk as those without a previous history. The risk for recurrent hemorrhages is even higher in those who have had more than one prior ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/70\">",
"     70",
"    </a>",
"    ]. Recurrent hemorrhage is also more likely with increasing number of microhemorrhages and in patients with posterior white matter hypodensity on CT scan. As noted above, carriers of the &epsilon;2 or &epsilon;4 APOE alleles are also at increased risk compared to the more common APOE",
"    <span class=\"nowrap\">",
"     &epsilon;3/&epsilon;3",
"    </span>",
"    genotype (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Apolipoprotein E'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of CAA should be suspected clinically in patients over the age of 60 who have multiple lobar hemorrhages in the absence of an obvious cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/71\">",
"     71",
"    </a>",
"    ]. According to proposed diagnostic criteria for CAA (",
"    <a class=\"graphic graphic_table graphicRef53541 \" href=\"mobipreview.htm?13/60/14284\">",
"     table 1",
"    </a>",
"    ), the disease can be definitively diagnosed only by full postmortem examination of the brain. However, there are two approaches toward making the diagnosis of \"probable CAA\" during life: gradient-echo MRI and examination of tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gradient-echo MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gradient-echo MRI accentuates the signal dropout caused by iron-containing deposits left by old hemorrhages (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81579 \" href=\"mobipreview.htm?10/9/10387\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To make the diagnosis of probable CAA (",
"    <a class=\"graphic graphic_table graphicRef53541 \" href=\"mobipreview.htm?13/60/14284\">",
"     table 1",
"    </a>",
"    ) with gradient-echo MRI, it is reasonable to look for the presence of two or more hemorrhages restricted to those regions typical of CAA (cortex or \"grey-white\" junction) and entirely sparing regions typical of hypertensive hemorrhage (basal ganglia, thalamus, or pons). These criteria are supported by both a limited amount of direct pathological correlation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/72\">",
"     72",
"    </a>",
"    ] and by more extensive correlation of APOE genotypes in clinically and pathologically diagnosed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/71\">",
"     71",
"    </a>",
"    ]. Application of these criteria to a population of patients with hereditary CAA of the Dutch type, using DNA analysis as the gold standard, found an overall sensitivity of 48 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/73\">",
"     73",
"    </a>",
"    ]. However, nearly half of the mutation carriers were asymptomatic. Among symptomatic individuals with CAA, the sensitivity was 93 percent.",
"   </p>",
"   <p>",
"    The gradient-echo images should be reviewed with some care, since lesions and structures other than intraparenchymal hemorrhage can produce signal dropout. These include hemosiderosis within a brain sulcus (a frequent consequence of subarachnoid extension of a lobar hemorrhage), flow-void from a cortical vessel, or adjacent air in the nasal sinuses. When establishing the presence of at least two hemorrhages, lesions that do not clearly represent independent hemorrhagic foci (for example, small blood deposits close to a larger hematoma) should not be counted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Microhemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inclusion of microhemorrhages in the MRI criteria for probable MRI increases the sensitivity of the criteria (",
"    <a class=\"graphic graphic_table graphicRef53541 \" href=\"mobipreview.htm?13/60/14284\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is important to note that the acceptance of only a single microhemorrhage as indicative of CAA may lead to erroneous assignment of nonamyloid microhemorrhages as CAA. Microbleeds may also occur in hypertensive microangiopathy and in infective endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/74\">",
"     74",
"    </a>",
"    ], although they tend to have a somewhat different anatomic distribution in these conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H2#H2\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its role in the diagnosis of CAA, a finding of multiple microhemorrhages on gradient-echo MRI may provide prognostic information. In a study of 94 consecutive survivors of primary lobar hemorrhage, the three-year cumulative risk of recurrent hemorrhage for patients with one, two, three to five, and six or greater hemorrhages on the baseline gradient-echo MRI was 14, 17, 38, and 51 percent, respectively (hazard ratio 1.7, 95% CI 1.2-2.4 for each increase in category) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/75\">",
"     75",
"    </a>",
"    ]. Higher numbers of hemorrhages also predicted a greater risk for future cognitive impairment, loss of functional independence, and death. Another study found that an incidental finding of multiple lobar microhemorrhages in an older adult was associated with a seven-fold risk of stroke-related death compared to individuals without lobar microhemorrhages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hemosiderosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that hemosiderosis can also represent a focus of bleeding related to CAA. Accumulation of evidence from small case series suggests an association between superficial siderosis and CAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. In a retrospective case-control study, superficial siderosis was detected on MRI in 60 percent of patients with pathologically-confirmed CAA, but in none of the cases of ICH that were pathologically determined to be not due to CAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/80\">",
"     80",
"    </a>",
"    ]. However, superficial siderosis can have a number of other unrelated causes (eg, prior trauma, vascular malformation) and the prognostic significance of this finding, and its association with CAA requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Examination of tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evacuated hematoma specimens and accompanying leptomeningeal or parenchymal tissue from elderly patients should routinely be examined with Congo red stain for CAA. Based upon data from a postmortem model, nearly all blocks of tissue from brains with CAA-related hemorrhage demonstrate some degree of CAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/3\">",
"     3",
"    </a>",
"    ], often with evidence of advanced disease such as complete amyloid replacement of the smooth muscle layer or the appearance of vessel breakdown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Signs of advanced disease are rare in single tissue specimens from asymptomatic elderly brains; thus, their presence points toward a degree of CAA severe enough to cause hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because a bleeding tendency can cause or contribute to bleeding initiated by CAA, evaluation for a bleeding disorder (platelet count, prothrombin time, and activated partial thromboplastin time) should be performed in every patient with an ICH.",
"   </p>",
"   <p>",
"    Decreased levels of cerebrospinal fluid (CSF) amyloid &szlig;42 and &szlig;40 protein are found in Alzheimer disease. One study found that these levels were decreased to an even greater extent in patients with CAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/84\">",
"     84",
"    </a>",
"    ]. In combination with the finding of increased total tau levels, CSF analysis distinguished patients with CAA from normal controls with a high degree of accuracy. These findings await independent confirmation.",
"   </p>",
"   <p>",
"    Positron emission tomography using 11C-Pittsburgh compound B (PIB), a ligand that binds to beta-amyloid, demonstrates increased uptake in patients with CAA-related hemorrhage compared with normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Compared with patients with Alzheimer disease, median binding of PIB is lower in CAA, and may differ in its distribution. In one study, microbleed sites in patients with CAA occurred preferentially in local regions of concentrated amyloid detected by PIB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/43\">",
"     43",
"    </a>",
"    ]. More studies are needed to define a potential role for this imaging technique in CAA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other relatively common causes of nontraumatic lobar hemorrhage include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lobar extension of a putaminal hemorrhage",
"     </li>",
"     <li>",
"      Hemorrhagic transformation of an ischemic stroke",
"     </li>",
"     <li>",
"      Arteriovenous malformation (AVM)",
"     </li>",
"     <li>",
"      Hemorrhagic tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Differentiation of CAA from these conditions depends upon the clinical setting (eg, most first AVM-related hemorrhages occur before age 35 to 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/87\">",
"     87",
"    </a>",
"    ]) and radiographic appearance. Gradient-echo MRI can be helpful in this regard by establishing the presence and distribution of previous hemorrhages. Another helpful study is a follow-up MRI performed two to three months after the primary hemorrhage to rule out underlying vascular malformation or tumor.",
"   </p>",
"   <p>",
"    Multiple hemorrhages can be seen with CNS vasculitis, hypertensive encephalopathy, multiple cavernous malformations, or coagulopathy. These conditions generally can be distinguished from CAA by the clinical setting and distribution of hemorrhages, which typically do not follow the same anatomic pattern as CAA (restriction to cortical or grey-white regions).",
"   </p>",
"   <p>",
"    There is as yet no clearly defined clinical role for genetic testing in CAA. In particular, APOE genotype is neither sensitive nor specific for the diagnosis of CAA, as the &epsilon;2 and &epsilon;4 alleles are present in only a subset of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Although, as noted above, AD is relatively common in CAA, only about 25 percent of CAA patients appear to have clinical histories of dementia prior to their first hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, dementia is not included in the diagnostic criteria for CAA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute CAA-related hemorrhage is treated like other acute intracerebral hemorrhages, with attention to intracranial pressure and loose control of blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .) Short-term empiric use of anticonvulsants is reasonable in lobar hemorrhage, particularly if the patient is at risk for aspiration or other medical complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical hematoma resection appears to carry little or no additional risk in CAA compared with other types of intracerebral hemorrhage and can be performed when indicated. In one series of 37 patients who were treated surgically, for example, 54 percent had a good outcome and only 11 percent died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/88\">",
"     88",
"    </a>",
"    ]. Age &ge;75 and intraventricular hemorrhage were associated with a worse prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Avoidance of anticoagulants and antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high recurrence rate, the general rule for patients with diagnosed CAA is to avoid anticoagulant and antiplatelet agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      increases both the frequency (approximately 7- to 10-fold) and severity (approximately 60 percent mortality) of cerebral hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/36,89\">",
"       36,89",
"      </a>",
"      ], and should be avoided, if possible, in patients with CAA.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      at commonly prescribed doses increases the risk of hemorrhage to a lesser extent. In one prospective cohort of patients with primary lobar ICH, aspirin was associated with an increased risk of ICH recurrence (HR = 3.95; 95% CI: 1.6 to 8.3) when controlling for other hemorrhage risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/70\">",
"       70",
"      </a>",
"      ]. Aspirin use can nonetheless be considered in selected patients with CAA if they have clear indications for antiplatelet therapy. Similar caution is warranted with the nonsteroidal antiinflammatory drugs. Among these agents, the nonacetylated salicylates (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/43/42677?source=see_link\">",
"       choline magnesium trisalicylate",
"      </a>",
"      ) do not appear to affect platelet function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the vascular pathology in CAA does not appear to be pathogenetically linked to hypertension, control of blood pressure within normal limits is nonetheless advisable. Recent support for lowering of blood pressure in patients diagnosed with CAA came from a secondary analysis of data from the PROGRESS trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/6\">",
"     6",
"    </a>",
"    ]. Randomization to active treatment (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35846?source=see_link\">",
"     indapamide",
"    </a>",
"    ) when there was either no indication or a contraindication to diuretics in this study resulted in a 77 percent reduction in the risk of probable CAA-related ICH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3469001\">",
"    <span class=\"h2\">",
"     Avoiding statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient data to recommend general restrictions on the use of statin agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher risk of ICH was observed in atorvastatin-treated patients in a secondary prevention trial of patients with ischemic cerebrovascular disease (SPARCL trial) and in the Heart Protection Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. In the former study, the hazard ratio for ICH was higher for those who entered the study with hemorrhagic as opposed to ischemic stroke (4.1 versus 1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/91\">",
"     91",
"    </a>",
"    ]. On the other hand, one case-control study found that statin use prior to ICH was associated with reduced mortality (OR 0.47) and increased probability of a favorable outcome (OR 2.08) with similar results found in a meta-analysis of published studies of ICH and statin use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/93\">",
"     93",
"    </a>",
"    ]. In contrast, a previously published study had found that low LDL cholesterol levels on admission were associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the conflicting data, it seems reasonable to weigh the benefits of statin therapy against the possible risks in individual patients with cerebral amyloid angiopathy because there is a high risk of ICH recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/95-97\">",
"     95-97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;While data are limited, available evidence suggests that the rare inflammatory forms of CAA (sometimes called Abeta-related angiitis) may be responsive to immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Perivascular/vascular inflammation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The largest series involved 12 patients with well-documented CAA-related perivascular inflammation and mean follow-up of 47 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/52\">",
"     52",
"    </a>",
"    ]. Treatment with glucocorticoids or pulsed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    resulted in sustained clinical improvement in seven patients, improvement with subsequent clinical flares in three, and no clinical response in two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/52\">",
"     52",
"    </a>",
"    ]. Other immunosuppressive treatments that have been effective in isolated cases include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37001/abstract/54\">",
"     54",
"    </a>",
"    ]. Approximately 70 percent of patients improve with treatment; a clinical response is typically seen in one to three weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Possible specific therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The future appears promising for the development of specific treatments for CAA. Drugs likely to emerge for blocking amyloid beta formation, deposition, or toxicity in AD will be strong candidates for secondary prevention trials in CAA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral amyloid angiopathy (CAA), although usually asymptomatic, is an important cause of primary lobar intracerebral hemorrhage (ICH) in the elderly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of symptomatic CAA increases with age; it is relatively unusual in individuals younger than 60 years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAA can occur as a sporadic disorder, with or without associated Alzheimer disease (AD), or as a familial syndrome. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAA is characterized by the deposition of congophilic material in small to medium-sized blood vessels of the brain and leptomeninges. This weakens the structure of the vessel wall and makes them prone to bleeding. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAA usually manifests with a spontaneous lobar hemorrhage. This location helps distinguish CAA-related ICH from hypertensive ICH that more commonly arises in the putamen, thalamus, and pons. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intracerebral hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transient neurologic symptoms are another potential manifestation of CAA. These are recurrent, brief (minutes), often stereotyped spells of weakness, numbness, paresthesias, or other cortical symptoms that can spread smoothly over contiguous body parts. The pathogenesis of these spells is not certain; they are not believed to be transient ischemic attacks in most cases. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Transient neurologic symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAA and Alzheimer disease frequently co-exist. CAA may also be associated with a vascular dementia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dementia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAA is suspected clinically in a patient over the age of 60 with a spontaneous lobar hemorrhage, particularly if there is not associated hypertension. Recurrent lobar hemorrhages in an older patient are particularly likely to represent CAA. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the diagnosis of CAA is made definitively by pathologic examination, a probable diagnosis of CAA can be made when MRI demonstrates the presence of two or more hemorrhages or microhemorrhages restricted to those regions typical of CAA (cortex or \"grey-white\" junction) and entirely sparing regions typical of hypertensive hemorrhage (basal ganglia, thalamus, or pons) (",
"      <a class=\"graphic graphic_table graphicRef53541 \" href=\"mobipreview.htm?13/60/14284\">",
"       table 1",
"      </a>",
"      ). Hemorrhage involving the cortical sulci (&ldquo;superficial siderosis&rdquo;) can also be suggestive of CAA. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Gradient-echo MRI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Microhemorrhages'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      MRI studies are also performed in patients with lobar ICH to exclude other causes (eg, vascular malformation, tumor). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The acute management of a patient with CAA-related ICH is similar to that as for other spontaneous ICH. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"       \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CAA-related ICH are frequently recurrent. Because anticoagulant and antiplatelet agents increase the frequency and severity of ICH, these (particularly anticoagulant agents) should be avoided in individuals who have probable CAA. Control of blood pressure may also limit the risk of ICH. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Avoidance of anticoagulants and antiplatelet agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Blood pressure control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another presentation of CAA is as an inflammatory leukoencephalopathy that manifests with subacute cognitive decline or seizure. Immunosuppressive therapy has been reported to be helpful in some patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Perivascular/vascular inflammation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/1\">",
"      Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011; 70:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/2\">",
"      Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012; 83:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/3\">",
"      Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997; 28:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/4\">",
"      Ferreiro JA, Ansbacher LE, Vinters HV. Stroke related to cerebral amyloid angiopathy: the significance of systemic vascular disease. J Neurol 1989; 236:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/5\">",
"      Broderick J, Brott T, Tomsick T, Leach A. Lobar hemorrhage in the elderly. The undiminishing importance of hypertension. Stroke 1993; 24:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/6\">",
"      Arima H, Tzourio C, Anderson C, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke 2010; 41:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/7\">",
"      Obici L, Demarchi A, de Rosa G, et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 2005; 58:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/8\">",
"      Melchor JP, McVoy L, Van Nostrand WE. Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. J Neurochem 2000; 74:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/9\">",
"      Van Nostrand WE, Melchor JP, Cho HS, et al. Pathogenic effects of D23N Iowa mutant amyloid beta -protein. J Biol Chem 2001; 276:32860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/10\">",
"      Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 2003; 361:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/11\">",
"      Davis J, Xu F, Deane R, et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 2004; 279:20296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/12\">",
"      Greenberg SM, Briggs ME, Hyman BT, et al. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996; 27:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/13\">",
"      Premkumar DR, Cohen DL, Hedera P, et al. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996; 148:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/14\">",
"      Nicoll JA, Burnett C, Love S, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997; 41:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/15\">",
"      Greenberg SM, Vonsattel JP, Segal AZ, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998; 50:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/16\">",
"      Greenberg SM, Rebeck GW, Vonsattel JP, et al. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995; 38:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/17\">",
"      Biffi A, Sonni A, Anderson CD, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 2010; 68:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/18\">",
"      Maxwell SS, Jackson CA, Paternoster L, et al. Genetic associations with brain microbleeds: Systematic review and meta-analyses. Neurology 2011; 77:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/19\">",
"      O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000; 342:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/20\">",
"      Biffi A, Anderson CD, Jagiella JM, et al. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol 2011; 10:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/21\">",
"      Woo D, Kaushal R, Chakraborty R, et al. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke 2005; 36:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/22\">",
"      Rosand J. Epistasis is coming: are we ready? Stroke 2005; 36:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/23\">",
"      McCarron MO, Nicoll JA, Ironside JW, et al. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE epsilon2 with putative clinical risk factors. Stroke 1999; 30:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/24\">",
"      Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:9649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/25\">",
"      McCarron MO, Nicoll JA, Stewart J, et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol 1999; 58:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/26\">",
"      Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1995; 1:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/27\">",
"      Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 1997; 389:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/28\">",
"      Biffi A, Shulman JM, Jagiella JM, et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology 2012; 78:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/29\">",
"      Samarasekera N, Smith C, Al-Shahi Salman R. The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2012; 83:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/30\">",
"      Rosand J, Muzikansky A, Kumar A, et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol 2005; 58:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/31\">",
"      Weller RO, Nicoll JA. Cerebral amyloid angiopathy: both viper and maggot in the brain. Ann Neurol 2005; 58:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/32\">",
"      Itoh Y, Yamada M, Hayakawa M, et al. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 1993; 116:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/33\">",
"      Yamada M, Itoh Y, Otomo E, et al. Subarachnoid haemorrhage in the elderly: a necropsy study of the association with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 1993; 56:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/34\">",
"      Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc 1979; 54:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/35\">",
"      Greenberg SM, Finklestein SP, Schaefer PW. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996; 46:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/36\">",
"      Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000; 55:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/37\">",
"      Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 1995; 45:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/38\">",
"      Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/39\">",
"      Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 1991; 83:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/40\">",
"      Jeerakathil T, Wolf PA, Beiser A, et al. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 2004; 35:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/41\">",
"      Walker DA, Broderick DF, Kotsenas AL, Rubino FA. Routine use of gradient-echo MRI to screen for cerebral amyloid angiopathy in elderly patients. AJR Am J Roentgenol 2004; 182:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/42\">",
"      Sveinbjornsdottir S, Sigurdsson S, Aspelund T, et al. Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry 2008; 79:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/43\">",
"      Vernooij MW, van der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008; 70:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/44\">",
"      Poels MM, Ikram MA, van der Lugt A, et al. Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke 2011; 42:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/45\">",
"      Dierksen GA, Skehan ME, Khan MA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 2010; 68:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/46\">",
"      Yates PA, Sirisriro R, Villemagne VL, et al. Cerebral microhemorrhage and brain &beta;-amyloid in aging and Alzheimer disease. Neurology 2011; 77:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/47\">",
"      Vernooij MW, Haag MD, van der Lugt A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol 2009; 66:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/48\">",
"      Gregoire SM, J&auml;ger HR, Yousry TA, et al. Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry 2010; 81:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/49\">",
"      Greenberg SM, Nandigam RN, Delgado P, et al. Microbleeds versus macrobleeds: evidence for distinct entities. Stroke 2009; 40:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/50\">",
"      Greenberg SM, Vonsattel JP, Stakes JW, et al. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993; 43:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/51\">",
"      Eng JA, Frosch MP, Choi K, et al. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004; 55:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/52\">",
"      Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007; 68:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/53\">",
"      Greenberg SM, Rapalino O, Frosch MP. Case records of the Massachusetts General Hospital. Case 22-2010. An 87-year-old woman with dementia and a seizure. N Engl J Med 2010; 363:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/54\">",
"      Chung KK, Anderson NE, Hutchinson D, et al. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry 2011; 82:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/55\">",
"      Oh U, Gupta R, Krakauer JW, et al. Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 2004; 62:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/56\">",
"      Fountain NB, Eberhard DA. Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature. Neurology 1996; 46:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/57\">",
"      Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/58\">",
"      Hermann DM, Keyvani K, van de Nes J, et al. Brain-reactive &beta;-amyloid antibodies in primary CNS angiitis with cerebral amyloid angiopathy. Neurology 2011; 77:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/59\">",
"      Arvanitakis Z, Leurgans SE, Wang Z, et al. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011; 69:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/60\">",
"      Gray F, Dubas F, Roullet E, Escourolle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 1985; 18:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/61\">",
"      Smith EE, Nandigam KR, Chen YW, et al. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage. Stroke 2010; 41:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/62\">",
"      Poels MM, Ikram MA, van der Lugt A, et al. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology 2012; 78:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/63\">",
"      van Norden AG, van den Berg HA, de Laat KF, et al. Frontal and temporal microbleeds are related to cognitive function: the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. Stroke 2011; 42:3382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/64\">",
"      Kimberly WT, Gilson A, Rost NS, et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 2009; 72:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/65\">",
"      Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996; 46:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/66\">",
"      Pfeifer LA, White LR, Ross GW, et al. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002; 58:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/67\">",
"      Goos JD, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke 2009; 40:3455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/68\">",
"      Kase CS, Williams JP, Wyatt DA, Mohr JP. Lobar intracerebral hematomas: clinical and CT analysis of 22 cases. Neurology 1982; 32:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/69\">",
"      Massaro AR, Sacco RL, Mohr JP, et al. Clinical discriminators of lobar and deep hemorrhages: the Stroke Data Bank. Neurology 1991; 41:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/70\">",
"      Biffi A, Halpin A, Towfighi A, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010; 75:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/71\">",
"      Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 1998; 51:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/72\">",
"      Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001; 56:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/73\">",
"      van Rooden S, van der Grond J, van den Boom R, et al. Descriptive analysis of the Boston criteria applied to a Dutch-type cerebral amyloid angiopathy population. Stroke 2009; 40:3022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/74\">",
"      Klein I, Iung B, Labreuche J, et al. Cerebral microbleeds are frequent in infective endocarditis: a case-control study. Stroke 2009; 40:3461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/75\">",
"      Greenberg SM, Eng JA, Ning M, et al. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004; 35:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/76\">",
"      Altmann-Schneider I, Trompet S, de Craen AJ, et al. Cerebral microbleeds are predictive of mortality in the elderly. Stroke 2011; 42:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/77\">",
"      Feldman HH, Maia LF, Mackenzie IR, et al. Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease. Stroke 2008; 39:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/78\">",
"      Linn J, Herms J, Dichgans M, et al. Subarachnoid hemosiderosis and superficial cortical hemosiderosis in cerebral amyloid angiopathy. AJNR Am J Neuroradiol 2008; 29:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/79\">",
"      Vernooij MW, Ikram MA, Hofman A, et al. Superficial siderosis in the general population. Neurology 2009; 73:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/80\">",
"      Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/81\">",
"      Mandybur TI. Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol 1986; 45:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/82\">",
"      Vonsattel JP, Myers RH, Hedley-Whyte ET, et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991; 30:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/83\">",
"      Natt&eacute; R, Vinters HV, Maat-Schieman ML, et al. Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Stroke 1998; 29:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/84\">",
"      Verbeek MM, Kremer BP, Rikkert MO, et al. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 2009; 66:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/85\">",
"      Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/86\">",
"      Ly JV, Donnan GA, Villemagne VL, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010; 74:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/87\">",
"      Graf CJ, Perret GE, Torner JC. Bleeding from cerebral arteriovenous malformations as part of their natural history. J Neurosurg 1983; 58:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/88\">",
"      Izumihara A, Ishihara T, Iwamoto N, et al. Postoperative outcome of 37 patients with lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Stroke 1999; 30:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/89\">",
"      Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/90\">",
"      Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/91\">",
"      Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/92\">",
"      Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/93\">",
"      Biffi A, Devan WJ, Anderson CD, et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology 2011; 76:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/94\">",
"      Ram&iacute;rez-Moreno JM, Casado-Naranjo I, Portilla JC, et al. Serum cholesterol LDL and 90-day mortality in patients with intracerebral hemorrhage. Stroke 2009; 40:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/95\">",
"      Westover MB, Bianchi MT, Eckman MH, Greenberg SM. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol 2011; 68:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/96\">",
"      Goldstein LB. Statins after intracerebral hemorrhage: to treat or not to treat. Arch Neurol 2011; 68:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37001/abstract/97\">",
"      Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8:453.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1128 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_37001=[""].join("\n");
var outline_f36_8_37001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mutant amyloid precursor protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Apolipoprotein E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL AND RADIOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Microhemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transient neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Perivascular/vascular inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gradient-echo MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Microhemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Examination of tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Avoidance of anticoagulants and antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3469001\">",
"      Avoiding statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Possible specific therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1128\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1128|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/37/20051\" title=\"diagnostic image 1\">",
"      CT CAA-related ICH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/27/29111\" title=\"diagnostic image 2\">",
"      CAA perivascular inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/9/10387\" title=\"diagnostic image 3\">",
"      Gradient echo MRI in CAA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1128|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/60/14284\" title=\"table 1\">",
"      Boston criteria CAA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_8_37002="Seasonal influenza vaccination in adults";
var content_f36_8_37002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Seasonal influenza vaccination in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/37002/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/37002/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/37002/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/37002/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/8/37002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/8/37002/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/8/37002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is an acute respiratory illness caused by influenza A or B viruses. It occurs in outbreaks and epidemics nearly every year, mainly during the winter season in temperate climates. Influenza viruses change their antigenic characteristics frequently, and their subsequent spread depends upon the susceptibility of the population to viruses with novel antigens. Annual influenza vaccination is an important public health measure for preventing influenza infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The protection provided by influenza vaccines is based upon induction of virus-neutralizing antibodies, mainly against the viral hemagglutinin.",
"   </p>",
"   <p>",
"    The role of influenza vaccination in the prevention of seasonal influenza will be reviewed here. The use of influenza vaccine in immunocompromised hosts, pregnant women, patients with chronic liver disease, patients with end-stage renal disease, healthcare workers, and travelers is discussed separately. (See associated topic reviews.)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of influenza in adults, the role of antiviral agents for the prevention and treatment of influenza, and vaccines against the 2009-2010 pandemic H1N1 influenza (\"swine influenza\") virus and H5N1 avian influenza are also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link&amp;anchor=H413651#H413651\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=see_link\">",
"     \"Avian influenza vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775063374\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Influenza activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization (WHO) and its reporting network, tracks influenza virus isolates throughout the world to monitor disease activity and to predict the appropriate components for the annual influenza vaccine. This information, which is updated weekly during influenza season, is available on the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly\">",
"     CDC&rsquo;s web site",
"    </a>",
"    . In addition, FluNet, a database for global influenza virus surveillance, is available on the",
"    <a class=\"external\" href=\"file://www.who.int/influenza/gisrs_laboratory/flunet/en/\">",
"     WHO&rsquo;s web site",
"    </a>",
"    . The typical seasonal trends of influenza activity in the United States are shown in the following Figure (",
"    <a class=\"graphic graphic_figure graphicRef60877 \" href=\"mobipreview.htm?12/3/12349\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Since July 2011, the CDC has reported cases of H3N2 variant (H3N2v) influenza A infection caused by reassortment of swine-origin H3N2 influenza A viruses and pandemic H1N1 influenza A viruses, most of which have occurred since July 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. All patients reported direct or indirect contact with swine, and the majority attended fairs where swine were present. The current seasonal influenza vaccines do not provide seroprotection against these strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link&amp;anchor=H104949276#H104949276\">",
"     \"Epidemiology of influenza\", section on 'H3N2 variant influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antigenic composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza virus is remarkable for its high rate of mutation, compromising the ability of the immune system to protect against new variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/8\">",
"     8",
"    </a>",
"    ]. As a consequence, new vaccines are produced each year to match circulating viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. The decision of which influenza antigens to include in the vaccines is made in advance of the influenza season and is based upon global surveillance of influenza viruses and the emergence and spread of new strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current influenza vaccines are trivalent, containing two influenza A virus antigens and one influenza B virus antigen. In 2012, the US Food and Drug Administration (FDA) approved quadrivalent formulations of both the live-attenuated influenza vaccine and the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    ; these vaccines contain two strains of influenza A virus and two strains of influenza B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Both vaccines are expected to be available for the 2013 to 2014 influenza season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO recommends that trivalent influenza vaccines for use during the",
"    <strong>",
"     2012 to 2013",
"    </strong>",
"    influenza season in the northern hemisphere (November to April) and the",
"    <strong>",
"     2013",
"    </strong>",
"    influenza season in the southern hemisphere (May to October) contain the following antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       A/California/7/2009",
"      </span>",
"      (H1N1)-like virus (against 2009 pandemic H1N1 influenza)",
"     </li>",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       A/Victoria/361/2011",
"      </span>",
"      (H3N2)-like virus",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       B/Wisconsin/1/2010-like",
"      </span>",
"      virus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The WHO also recommends that when quadrivalent influenza vaccines are used during the",
"    <strong>",
"     2013",
"    </strong>",
"    influenza season in the southern hemisphere (May to October), they contain the three antigens described above plus a",
"    <span class=\"nowrap\">",
"     B/Brisbane/60/2008-like",
"    </span>",
"    virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO recommends that trivalent influenza vaccines for use during the",
"    <strong>",
"     2013 to 2014",
"    </strong>",
"    influenza season in the northern hemisphere (November to April) contain the following antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       A/California/7/2009",
"      </span>",
"      (H1N1)-like virus (against 2009 pandemic H1N1 influenza)",
"     </li>",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       A/Texas/50/2012",
"      </span>",
"      (H3N2)-like virus that is antigenically similar to the cell-propagated prototype virus",
"      <span class=\"nowrap\">",
"       A/Victoria/361/2011",
"      </span>",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       B/Massachusetts/2/2012-like",
"      </span>",
"      virus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The H1N1 influenza A antigen is the same as the one used in the previous season&rsquo;s vaccines, but the H3N2 influenza A and influenza B antigens are different. The H3N2 influenza A antigen was modified because of antigenic changes in earlier",
"    <span class=\"nowrap\">",
"     A/Victoria/361/2011-like",
"    </span>",
"    vaccine viruses resulting from adaptation to propagation in eggs.",
"   </p>",
"   <p>",
"    <br/>",
"    The WHO also recommends that when quadrivalent influenza vaccines are used during the",
"    <strong>",
"     2013 to 2014",
"    </strong>",
"    influenza season in the northern hemisphere (November to April), they contain the three antigens described above plus a",
"    <span class=\"nowrap\">",
"     B/Brisbane/60/2008-like",
"    </span>",
"    virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Influenza A viruses, in particular, undergo periodic changes in the antigenic characteristics of their envelope glycoproteins, the hemagglutinin and the neuraminidase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/18\">",
"     18",
"    </a>",
"    ]. Among influenza A viruses that infect humans, three major subtypes of hemagglutinins (H1, H2, and H3) and two subtypes of neuraminidases (N1 and N2) have been described. Major changes in these glycoproteins are referred to as antigenic shifts, and minor changes are called antigenic drifts. Antigenic shifts are generally associated with epidemics and pandemics of influenza A, whereas antigenic drifts are associated with more localized outbreaks of varying extent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of influenza\", section on 'Antigenic shifts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology of influenza\", section on 'Antigenic drifts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Influenza B viruses have a lesser propensity for antigenic changes, and only antigenic drifts in the hemagglutinin have been described. More subtypes of hemagglutinins and neuraminidases can exist in avian influenza A viruses compared with the influenza A viruses that cause seasonal influenza infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\", section on 'Background'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current vaccination strategy is vulnerable to the emergence of epidemic or pandemic strains that are not represented in the current vaccine. Ongoing research is focused on developing a universal vaccine that would elicit protective antibodies directed against conserved viral proteins. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Immunogenicity, efficacy, and safety'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4445192\">",
"     'Universal vaccines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vaccine formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, two different types of influenza vaccine are available, inactivated vaccines and a live-attenuated vaccine (LAIV). The inactivated vaccines are available for intramuscular or intradermal injection, whereas LAIV is administered intranasally (",
"    <a class=\"graphic graphic_table graphicRef60449 \" href=\"mobipreview.htm?3/34/3630\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"mobipreview.htm?41/31/42494\">",
"     table 2",
"    </a>",
"    ). The choice of which influenza vaccine to administer to individual patients is discussed below. (See",
"    <a class=\"local\" href=\"#H775053590\">",
"     'Choice of vaccine formulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The available inactivated influenza vaccines in the United States are preparations of subvirion components (\"split product\" vaccines) that have been inactivated. The standard-dose inactivated influenza vaccines are approved by the FDA for use in adults of any age.",
"   </p>",
"   <p>",
"    The intranasally administered live-attenuated influenza vaccine (LAIV, FluMist) is approved by the FDA for healthy non-pregnant adults up to 49 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/19\">",
"     19",
"    </a>",
"    ]. This vaccine uses a master attenuated cold-adapted (CA) donor virus from which reassortants are generated that have hemagglutinin and neuraminidase antigens from strains that were circulating at the time that the annual vaccine was designed.",
"   </p>",
"   <p>",
"    Influenza vaccines have traditionally been produced in embryonated chicken eggs. In addition to the trivalent inactivated vaccines and the trivalent LAIV produced in eggs and given at the usual doses, several other formulations are available or are expected to be available soon in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       High-dose trivalent",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      &mdash; In December 2009, the FDA approved an intramuscular high-dose inactivated influenza vaccine (Fluzone high dose) for individuals &ge;65 years of age; the vaccine contains 60 mcg of each vaccine antigen instead of 15 mcg, which is the standard dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/20\">",
"       20",
"      </a>",
"      ]. The approval was based on data showing increased immunogenicity of the high-dose vaccine in older adults. (See",
"      <a class=\"local\" href=\"#H384358\">",
"       'High-dose vaccine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Intradermal low-dose trivalent",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      &mdash; In May 2011, the FDA approved an intradermal formulation of the inactivated influenza vaccine (Fluzone intradermal) for individuals between 18 and 64 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/21\">",
"       21",
"      </a>",
"      ]. This vaccine uses one-fifth of the usual amount of vaccine antigens and is delivered using an ultra-fine needle that is 1.5 mm in length [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/22\">",
"       22",
"      </a>",
"      ]. It is supplied in a single dose, preservative-free syringe. (See",
"      <a class=\"local\" href=\"#H385648\">",
"       'Intradermal delivery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Trivalent",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      <strong>",
"       produced in cultured cells",
"      </strong>",
"      &mdash; In November 2012, the FDA approved a trivalent inactivated influenza vaccine produced in cultured mammalian cells (Flucelvax) for individuals &ge;18 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H861848209\">",
"       'Cell-based inactivated vaccine'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H34\">",
"       'Alternative production methods'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Trivalent",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      <strong>",
"       produced using recombinant DNA technology and a baculovirus expression system",
"      </strong>",
"      &mdash; In January 2013, the FDA approved a trivalent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/11/39093?source=see_link\">",
"       recombinant hemagglutinin influenza vaccine",
"      </a>",
"      (Flublok), which is produced using recombinant DNA technology and a baculovirus expression system that produces virus-like particles, for individuals 18 through 49 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H692172\">",
"       'Recombinant hemagglutinin vaccine'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H34\">",
"       'Alternative production methods'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Quadrivalent LAIV and inactivated influenza vaccines",
"      </strong>",
"      &mdash; In February 2012, the FDA approved a quadrivalent formulation of the live-attenuated influenza vaccine and in December 2012, they approved a quadrivalent formulation of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      ; these vaccines contain two strains of influenza A virus and two strains of influenza B virus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. Both vaccines are expected to be available for the 2013 to 2014 influenza season [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9,14\">",
"       9,14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antigenic composition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the formulations available in the United States contain adjuvants, which are substances that amplify the immune response to an antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/26\">",
"     26",
"    </a>",
"    ]. Adjuvants are used in certain influenza vaccine preparations outside the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=see_link\">",
"     \"Avian influenza vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775065130\">",
"    <span class=\"h2\">",
"     Vaccine supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some influenza seasons, supply of the inactivated vaccine has been limited, in part because of the small number of manufacturers of the vaccines. Updates on the influenza vaccine supply are available on the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/about/qa/vaxsupply.htm\">",
"     CDC&rsquo;s web site",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A possible way to increase the supply of the inactivated vaccine is to administer lower doses via either the intramuscular or the intradermal route. This approach is discussed below. (See",
"    <a class=\"local\" href=\"#H78880699\">",
"     'Reduced dose vaccines'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H385648\">",
"     'Intradermal delivery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184898325\">",
"    <span class=\"h1\">",
"     APPROACH TO IMMUNIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775052687\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for immunization is that, although influenza usually causes an acute self-limited febrile illness, elderly adults and individuals with underlying health problems are at increased risk for complications of influenza, decline in physical functioning, and even death. In 2010, the United States Advisory Committee on Immunization Practices (ACIP) expanded the recommendation for influenza vaccination to include all individuals six months of age and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9,27\">",
"     9,27",
"    </a>",
"    ]. This represents a change from previous guidelines, which recommended influenza vaccination for individuals at increased risk of influenza complications and close contacts of such individuals. High-risk individuals, their close contacts, and healthcare workers should remain high priority recipients in vaccination campaigns. (See",
"    <a class=\"local\" href=\"#H775072460\">",
"     'High-priority groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775052810\">",
"    <span class=\"h2\">",
"     Schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outbreaks of influenza generally occur during the winter months in the northern and southern hemispheres (which occur at different times of the year). A single dose of an influenza vaccine should be administered to adults annually and offered as soon as the vaccine becomes available, ideally by October in the northern hemisphere and May in the southern hemisphere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. Vaccination should continue to be administered throughout the influenza season, the length of which varies from year to year. Evidence of significant influenza activity in the community should be used to determine how late in the season vaccination should be offered. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Influenza activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Travelers to tropical regions should be reminded that influenza occurs throughout the year in the tropics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, summertime outbreaks of influenza have occurred on cruise ships in the northern and southern hemispheres and during pandemics, such as the 2009-2010 H1N1 influenza A pandemic. Repeat vaccination is not necessary in those who received routine vaccination at the appropriate time in the previous fall or winter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunizations for travel\", section on 'Influenza vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Influenza vaccines can be given to individuals with minor respiratory illnesses with or without fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/30\">",
"     30",
"    </a>",
"    ]. However, vaccination should be delayed until symptoms have resolved in patients with moderate or severe acute illness, with or without fever, to avoid confusion between the underlying illness and adverse effects of the vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775053590\">",
"    <span class=\"h2\">",
"     Choice of vaccine formulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of vaccine formulation depends upon several factors, including age, comorbidities, pregnancy, and risk of adverse reactions (",
"    <a class=\"graphic graphic_table graphicRef60449 \" href=\"mobipreview.htm?3/34/3630\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       For healthy non-pregnant adults up to 49 years of age",
"      </strong>",
"      , we recommend either an inactivated vaccine or the live-attenuated influenza vaccine (LAIV) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       For all individuals &ge;50 years of age and for individuals with a contraindication to receiving LAIV",
"      </strong>",
"      (eg, immunocompromise; chronic cardiovascular, pulmonary, or metabolic disease; pregnancy; egg allergy), we recommend an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Contraindications and precautions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Individuals between 18 and 64 years of age",
"      </strong>",
"      can receive an intradermal formulation of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      (Fluzone intradermal) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/21\">",
"       21",
"      </a>",
"      ]. This vaccine can be used as an alternative to other inactivated vaccines, but the ACIP has not stated a preference for this vaccine over the standard inactivated vaccines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H385648\">",
"       'Intradermal delivery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Individuals &ge;65 years of age",
"      </strong>",
"      can receive the intramuscular high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      (Fluzone high dose) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/20\">",
"       20",
"      </a>",
"      ]. However, the ACIP has not stated a preference for this vaccine over the standard dose inactivated influenza vaccine in older adults since there are no data demonstrating greater protection against influenza illness. (See",
"      <a class=\"local\" href=\"#H384358\">",
"       'High-dose vaccine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       For adults with egg allergy",
"      </strong>",
"      , we recommend a trivalent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      that was not produced in eggs (",
"      <a class=\"graphic graphic_table graphicRef79474 \" href=\"mobipreview.htm?41/31/42494\">",
"       table 2",
"      </a>",
"      ). For individuals aged 18 to 49 years, either the vaccine produced in cultured mammalian cells (Flucelvax) or the vaccine produced using recombinant DNA technology (Flublok) may be used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. For individuals &gt;49 years of age, Flucelvax should be used. Flucelvax is available for the 2012-2013 influenza season, while only a limited supply of Flublok is expected to be available towards the end of the 2012-2013 season [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/31\">",
"       31",
"      </a>",
"      ]. If an egg-free vaccine is not available, an inactivated influenza vaccine produced in eggs can be used with some precautions. As noted above, LAIV is",
"      <strong>",
"       not",
"      </strong>",
"      recommended in patients with egg allergy because its safety in such patients has not been evaluated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9\">",
"       9",
"      </a>",
"      ]. This is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"       \"Influenza vaccination in individuals with egg allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inactivated influenza vaccines do",
"      <strong>",
"       not",
"      </strong>",
"      appear to exacerbate chronic neurologic diseases such as multiple sclerosis and can therefore be given to individuals with such conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775073919\">",
"    <span class=\"h2\">",
"     Adminstration with other vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivated vaccines do not interfere with the immune response to other inactivated vaccines or to live vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    may therefore be administered at the same time, but at a different site, as other recommended vaccines. The deltoid muscle is the preferred site for intramuscular administration in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LAIV can be administered at the same time as other live and inactivated vaccines; however, if it is not administered on the same day as other live vaccines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    ), it should be administered at least four weeks later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775072460\">",
"    <span class=\"h2\">",
"     High-priority groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although annual influenza vaccination is recommended for all individuals &ge;6 months of age, when the vaccine supply is limited, those who are at increased risk for complications and household contacts and caregivers of such persons should be the highest priority recipients (",
"    <a class=\"graphic graphic_table graphicRef79334 \" href=\"mobipreview.htm?28/14/28908\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H775052687\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Individuals who are at increased risk for influenza complications include those at the extremes of age, pregnant women, immunocompromised hosts, those with certain chronic diseases, and others; the groups at high risk for influenza complications are presented in the following Table (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"mobipreview.htm?32/50/33579\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. Although there are no data regarding the risk for severe or complicated influenza among asplenic individuals, influenza is a risk factor for secondary bacterial pneumonia, which can be severe in such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Secondary bacterial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775072578\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon evidence that influenza infection is associated with excess complications and death in pregnant women, the ACIP recommends the inactivated influenza vaccination for pregnant women, regardless of the stage of pregnancy, and of women who might be pregnant during the influenza season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33\">",
"     33",
"    </a>",
"    ]. Influenza vaccination in pregnant women is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunizations during pregnancy\", section on 'Influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775072633\">",
"    <span class=\"h3\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP recommends the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    for immunocompromised patients, including HIV-infected individuals, patients with cancer, and transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33\">",
"     33",
"    </a>",
"    ]. LAIV is contraindicated in immunocompromised individuals. Influenza vaccination in the setting of immunocompromise is discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H775053590\">",
"     'Choice of vaccine formulation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunizations in HIV-infected patients\", section on 'Influenza vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=see_link&amp;anchor=H9#H9\">",
"     \"Immunizations in patients with cancer\", section on 'Influenza vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=see_link&amp;anchor=H12#H12\">",
"     \"Immunizations in solid organ transplant candidates and recipients\", section on 'Influenza'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunizations after hematopoietic cell transplantation\", section on 'Influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775072688\">",
"    <span class=\"h3\">",
"     Healthcare workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination is particularly important for individuals who might transmit influenza to persons at high risk for complications; such individuals include healthcare workers, workers at chronic healthcare facilities, providers of home care to persons at high risk, and household contacts of persons in high risk groups (",
"    <a class=\"graphic graphic_table graphicRef79334 \" href=\"mobipreview.htm?28/14/28908\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. The efficacy of vaccination has not been systematically studied in any of these groups, except for healthcare workers at long-term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In a systematic review, staff vaccination at elderly care facilities had a significant effect on influenza-like illness only when patients were also vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13322?source=see_link&amp;anchor=H8#H8\">",
"     \"Immunizations for healthcare providers\", section on 'Influenza vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CDC recommends that a signed declination from healthcare workers who do not accept influenza immunization should be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/40\">",
"     40",
"    </a>",
"    ]. Some have proposed mandatory vaccination programs for healthcare workers, although this is highly controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/41-45\">",
"     41-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H775055218\">",
"    <span class=\"h2\">",
"     Need for annual vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual immunization is necessary even if the previous year's vaccine contained one or more of the antigens to be administered because immunity declines during the year following vaccination. Annual vaccination reduces morbidity and mortality from influenza compared with no vaccination or perhaps even a first vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Annual vaccination is also associated with a mortality benefit in elderly adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Effect on mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMMUNOGENICITY, EFFICACY, AND SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because influenza vaccines produced in eggs take approximately nine months to manufacture, they necessarily contain antigens from strains that circulated during the previous year. The protective efficacy of the vaccine is largely determined by the relationship (closeness of \"fit\" or \"match\") between the strains in the vaccine and viruses that circulate in the outbreak. A study that compared the effectiveness of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    during influenza seasons with differing degrees of vaccine match illustrates the importance of the fit between circulating influenza virus strains and the vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/48\">",
"     48",
"    </a>",
"    ]. During the 2004-2005 influenza season, the antigenic match was only 5 percent compared with 91 percent during the 2006-2007 season, which resulted in a vaccine effectiveness of 10 versus 52 percent, respectively.",
"   </p>",
"   <p>",
"    A repeated finding in various studies is that vaccination produces a greater reduction in serologically confirmed influenza than in clinical influenza. Universal influenza vaccination in Ontario, Canada has also been shown to reduce the number of antibiotic prescriptions during periods of peak influenza activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205840196\">",
"    <span class=\"h2\">",
"     Effectiveness for the 2012-2013 season",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a case-control study of 2697 children and adults with acute respiratory illness enrolled between early December 2012 and mid-January 2013, the United States Centers for Disease Control and Prevention estimated that the effectiveness of the 2012-2013 seasonal influenza vaccines in preventing medically attended influenza infections in all age groups was 56 percent (95% CI 47-63 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/50\">",
"     50",
"    </a>",
"    ]. Effectiveness against influenza A was 47 percent (95% CI 35-58 percent) and against influenza B was 67 percent (95% CI 51-78 percent). Age-stratified effectiveness estimates against H3N2 influenza A were 46 percent for individuals from 18 to 49 years of age and 50 percent for individuals from 50 to 64 years of age, but only 9 percent for individuals &ge;65 years of age. H3N2 influenza was responsible for 98 percent of influenza A infections for which subtyping was performed. Effectiveness against H1N1 influenza A viruses was not assessed. The effectiveness against influenza B viruses was similar among different age groups (ages 18 to 49 years: 68 percent; ages 50 to 64 years: 75 percent; age 65 or older: 67 percent).",
"   </p>",
"   <p>",
"    Given the moderate overall effectiveness of the vaccine (and poor effectiveness against H3N2 influenza A in older adults), influenza infection will occur among some individuals who received the influenza vaccine. This highlights the importance of early antiviral therapy (regardless of vaccination status), particularly for those at risk for severe or complicated influenza infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Healthy adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the efficacy or immunogenicity of various influenza vaccines in different populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Trivalent inactivated vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many studies evaluating the efficacy of influenza vaccines in healthy adults have been published and efficacy is often estimated to be between 70 and 90 percent, a 2012 comprehensive review suggested that efficacy may be considerably lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/51\">",
"     51",
"    </a>",
"    ]. In a 2012 meta-analysis (performed by the same group that did the comprehensive review) that included eight randomized trials of the inactivated influenza vaccines in adults aged 18 to 64 years over nine influenza seasons, vaccine efficacy for preventing laboratory-confirmed influenza was 59 percent (95% CI 51-67 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/52\">",
"     52",
"    </a>",
"    ]. Of note, higher rates of efficacy and effectiveness have been reported in trials that used serologic endpoints; such trials were excluded from this meta-analysis because using serologic endpoints is likely to lead to an overestimation of benefit.",
"   </p>",
"   <p>",
"    The match between the antigens included in the influenza vaccines and circulating influenza strains has an important influence on the efficacy of the vaccines. In a 2010 Cochrane meta-analysis of clinical trials of inactivated influenza vaccines, efficacy for preventing influenza symptoms was 73 percent (95% CI 54-84 percent) when there was a good match, but only 44 percent (95% CI 23-59 percent) when there was not a good match [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case-control study in adults 40 years or older found that influenza vaccination was associated with a reduction in the rate of first acute myocardial infarction (adjusted odds ratio 0.81, 95% CI 0.77-0.85) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861848209\">",
"    <span class=\"h3\">",
"     Cell-based inactivated vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In November 2012, the US Food and Drug Administration (FDA) approved a trivalent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    produced in cultured mammalian cells (Flucelvax) for individuals &ge;18 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In a placebo-controlled trial that included 7728 adults, the efficacy of Flucelvax was 84 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], which is comparable to standard available influenza vaccines. In addition, in seven trials that included 6281 adults, rates of serious events in patients who received cell-based vaccine groups were similar to those who received egg-based vaccine or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/24\">",
"     24",
"    </a>",
"    ]. Several other randomized trials have demonstrated that the immunogenicity and efficacy of influenza vaccines produced using mammalian cell lines are comparable to vaccines produced using embryonated eggs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/55-59\">",
"     55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, egg-free vaccines are particularly useful for patients with egg allergies (see",
"    <a class=\"local\" href=\"#H775053590\">",
"     'Choice of vaccine formulation'",
"    </a>",
"    above). Other benefits of cell-based vaccines (eg, faster production time) are discussed below. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Alternative production methods'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692172\">",
"    <span class=\"h3\">",
"     Recombinant hemagglutinin vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2013, the FDA approved a second egg-free trivalent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/11/39093?source=see_link\">",
"     recombinant hemagglutinin influenza vaccine",
"    </a>",
"    (Flublok), which is produced using recombinant DNA technology and a baculovirus expression system that produces virus-like particles, for individuals 18 through 49 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/25\">",
"     25",
"    </a>",
"    ]. This vaccine was shown to be safe and immunogenic in a randomized trial that included 460 adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/60\">",
"     60",
"    </a>",
"    ]. In a randomized trial that included 4648 adults, Flublok was approximately 45 percent effective against all circulating influenza strains, despite substantial antigenic mismatch between the vaccine antigens and circulating viruses; 96 percent of influenza viruses isolated from trial participants contained antigens that differed from the vaccine antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/61\">",
"     61",
"    </a>",
"    ]. Adverse events were similar to those that occur with conventional egg-based inactivated influenza vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Live-attenuated vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared the live-attenuated influenza vaccine (LAIV) preparation with placebo in 4561 healthy, employed adults followed through an influenza season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/62\">",
"     62",
"    </a>",
"    ]. Vaccination was associated with significant reductions in severe febrile illnesses (19 percent), febrile upper respiratory tract illnesses (24 percent), and days of work lost for febrile upper respiratory tract illnesses (28 percent). The vaccine was well tolerated and appeared to protect against the prevailing strain of influenza A that season, despite the virus showing considerable drift from the vaccine strain.",
"   </p>",
"   <p>",
"    In a 2010 Cochrane meta-analysis of a limited number of trials, the efficacy of LAIV was 62 percent (95% CI 45-73 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the authors cautioned that conclusions cannot be drawn from these results because the few trials included in the analysis are not directly comparable because of heterogeneous definitions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Comparisons of inactivated and live-attenuated vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although in children the LAIV appears to be more effective than the inactivated vaccine, studies in adults have shown that the inactivated vaccine is either equivalent to or more effective than the live-attenuated vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H25#H25\">",
"     \"Seasonal influenza vaccination in children\", section on 'LAIV compared with IIV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comparisons of inactivated and live-attenuated vaccines have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial compared the intramuscular inactivated and intranasal live-attenuated influenza vaccines in 5210 normal subjects over five years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/63\">",
"       63",
"      </a>",
"      ]. In terms of preventing culture-positive influenza A, the inactivated and live-attenuated vaccines were 76 and 85 percent effective against H1N1 disease and 74 and 58 percent effective against H3N2 disease, respectively. The differences between the two vaccines were not statistically significant.",
"     </li>",
"     <li>",
"      A subsequent randomized trial was performed in 1247 healthy adults in Michigan during the 2004-2005 influenza season [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/64\">",
"       64",
"      </a>",
"      ]. Both vaccines had similar efficacy against culture-proven influenza A infection (74 percent), despite the fact that most circulating viruses were dissimilar to those included in the vaccines. In contrast, the inactivated vaccine was superior to the live-attenuated vaccine against culture-confirmed type B influenza infections (80 versus 40 percent efficacy).",
"     </li>",
"     <li>",
"      In another randomized trial that included 1952 adults in Michigan vaccinated during the 2007-2008 influenza season, the inactivated vaccine was superior to the live-attenuated vaccine against influenza infection as detected by viral culture, real-time polymerase chain reaction, or both (68 versus 36 percent absolute efficacy, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/65\">",
"       65",
"      </a>",
"      ]. During the same influenza season, 90 percent of isolates were influenza A H3N2 and 9 percent of isolates were influenza B. The absolute efficacy against the influenza A strain was 72 percent for the inactivated vaccine compared with 29 percent for the live-attenuated vaccine.",
"     </li>",
"     <li>",
"      In a large surveillance study of US military personnel during three influenza seasons between 2004 and 2007, immunization with the inactivated vaccine was associated with lower rates of healthcare visits for pneumonia and influenza compared with the live-attenuated vaccine (8.6 versus 19.4 per 1000 person-years in 2004-2005; 7.8 versus 10.9 per 1000 person-years in 2005-2006; and 8.0 versus 11.7 per 1000 person-years in 2006-2007) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/66\">",
"       66",
"      </a>",
"      ]. However, among individuals who had not been immunized the previous year, the effect of the live-attenuated vaccine was comparable to the inactivated vaccine during the 2005-2006 and 2006-2007 seasons. Whether these results can be generalized to other populations is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative performance of the vaccines may vary according to the age of the recipient, the level of pre-existing immunity, and the specific circulating virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 90 percent of influenza-related deaths occur among people over 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/69\">",
"     69",
"    </a>",
"    ] and elderly patients have increased morbidity from the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78890919\">",
"    <span class=\"h3\">",
"     Standard-dose inactivated vaccines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78890862\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    in elderly patients (in whom the live vaccine is not recommended) has been evaluated in a few randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/70-72\">",
"     70-72",
"    </a>",
"    ] and multiple large observational studies, both in the community and in long-term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/73-80\">",
"     73-80",
"    </a>",
"    ], as well as in sicker patients such as those with chronic lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/81-83\">",
"     81-83",
"    </a>",
"    ], with conflicting results.",
"   </p>",
"   <p>",
"    In a 2010 Cochrane meta-analysis of three randomized trials of inactivated influenza vaccines in elderly individuals, the vaccines were 58 percent effective against influenza (95% CI 34-73 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/84\">",
"     84",
"    </a>",
"    ]. Based on a meta-analysis of two randomized trials, the vaccines were 43 efficacious against influenza-like illness (95% CI 21-58 percent). Both the authors of the Cochrane review and the authors of a 2012 systematic review concluded that there are inadequate high-quality data from randomized trials and observational studies to assess the efficacy of influenza vaccines in individuals &ge;65 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/52,84\">",
"     52,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2008 case-control study evaluated 1173 cases and 2346 controls among community-dwelling elderly individuals during three pre-influenza periods and influenza seasons, also during a period when there was good antigenic match between the influenza vaccine and circulating viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/79\">",
"     79",
"    </a>",
"    ]. This study also found that influenza vaccination did not reduce the risk of pneumonia (including those who did not require hospitalization), after adjusting for the presence and severity of comorbidities. In contrast, in a 2012 cohort study of community-dwelling elderly individuals that evaluated 12.6 million person-influenza seasons, vaccination was associated with a reduction in the composite endpoint of hospitalization (for pneumonia and influenza) and death during influenza season (adjusted odds ratio 0.86, 95% CI 0.79-0.92) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since protection against influenza is suboptimal in the elderly, it is not surprising that the outbreaks of influenza have occurred in nursing homes where 80 to 98 percent of residents were vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Healthcare workers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Effect on mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been difficult to demonstrate an improvement in survival after influenza vaccination in elderly patients in randomized trials because mortality is a rare end-point. Some studies have observed a significant reduction in death from influenza or pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/84\">",
"     84",
"    </a>",
"    ], but some experts have suggested that frailty selection bias in cohort studies has led to an overestimation of any mortality benefit of influenza vaccination in elderly adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/86\">",
"     86",
"    </a>",
"    ]. The following studies illustrate the range of findings and some of the limitations in study design:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pooled cohort study demonstrated a small but significant reduction in mortality in vaccinated elderly individuals (1.0 versus 1.6 percent in unvaccinated individuals) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/74\">",
"       74",
"      </a>",
"      ]. A sensitivity analysis was performed to detect unmeasured confounders. Even when a higher rate of confounders was assumed, there was still a significant reduction in mortality. Other studies have supported this finding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The difficulty of using observational data to evaluate the effect of influenza vaccine on mortality is illustrated by a prospective case-control study of patients (mostly over the age of 65) with community-acquired pneumonia (CAP). The study assessed the impact of influenza vaccination on in-hospital mortality in patients admitted during the off-season for influenza [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/88\">",
"       88",
"      </a>",
"      ]. A significant mortality reduction was observed in vaccinated patients (OR 0.49, 95% CI 0.30-0.79). However, when adjustments were made to address confounding factors (eg, functional and socioeconomic status), the mortality benefit became nonsignificant (adjusted OR 0.81, 95% CI 0.35-1.85). This study shows that the presence of bias may overestimate the mortality benefit of influenza vaccination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large cohort study of community-dwelling elderly individuals did not detect a mortality benefit from influenza vaccination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/85\">",
"       85",
"      </a>",
"      ]. An important limitation of this study was the likely underreporting of vaccination status, which could have contributed to the vaccine appearing ineffective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Annual revaccination has been associated with a reduction in mortality in elderly adults. A report from the Netherlands of over 26,000 community-dwelling elderly individuals evaluated the association between the number of consecutive annual influenza vaccinations and all-cause mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/47\">",
"       47",
"      </a>",
"      ]. After adjustment for age, sex, and comorbidities, the following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A first vaccination was associated with a nonsignificant annual reduction in mortality risk of 10 percent, while revaccination was associated with a significant 24 percent reduction in mortality overall and a 28 percent reduction during epidemics. There was also a trend toward further benefit with each consecutive vaccination.",
"     </li>",
"     <li>",
"      Vaccination interruption was associated with a strong and significant increase in mortality risk (adjusted hazard ratio 1.25, 95% CI 1.10-1.42), an effect that was reversed with restarting annual vaccination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78890805\">",
"    <span class=\"h4\">",
"     Waning of antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been concern that the response to annual vaccination might attenuate over time, particularly in elderly individuals. However, a 2008 literature review that included studies of individuals &gt;60 years old found that after influenza vaccination, seroprotection was maintained for at least four months (and often for longer) in all eight studies that assessed antibody responses to the H3N2 component and in five of seven studies that assessed responses to the H1N1 and B components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/91\">",
"     91",
"    </a>",
"    ]. Following successful immunization, seroprotection rates of 70 to 100 percent were maintained not just at four months (two studies), but also at five months (two studies) and at &gt;6 months (four studies) for the H3N2 and H1N1 influenza A vaccine components. Seroprotection rates were less consistent for the influenza B vaccine component. Both studies that failed the criteria for seroprotection at four or more months following immunization for the H1N1 influenza A and influenza B components also reported failed seroprotection at one month following immunization. This suggests that patients who did not have seroprotective antibodies at four months failed to mount an adequate immune response following vaccination (as opposed to having developed seroprotective antibodies following vaccination that subsequently waned).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384358\">",
"    <span class=\"h3\">",
"     High-dose vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In December 2009, the FDA approved a high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    for individuals &ge;65 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H775053590\">",
"     'Choice of vaccine formulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a trial that compared a high dose (60 mcg of hemagglutinin per strain) with the standard dose (15 mcg of hemagglutinin per strain) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    in adults &ge;65 years of age, improved rates of seroconversion and an increase in mean hemagglutination inhibition titers one month following vaccination were observed in individuals who received the high dose vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/92\">",
"     92",
"    </a>",
"    ]. Mild to moderate local reactions were more common in those who received the high dose vaccine. The immunogenicity of the high-dose vaccine in HIV-infected individuals is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link&amp;anchor=H14#H14\">",
"     \"Immunizations in HIV-infected patients\", section on 'Efficacy, immunogenicity, and safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another study showed that administering an increased dose of a purified influenza A H1N1 hemagglutinin vaccine enhanced antibody responses not just to the vaccine virus, but also to antigenically distinct influenza A H1N1 variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H385648\">",
"    <span class=\"h3\">",
"     Intradermal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternate methods of vaccine administration have been developed in an attempt to improve immunogenicity, particularly in older adults in whom the immune response may be attenuated. Intradermal administration may be more effective than intramuscular delivery, probably because of stimulation of dendritic cells, which are specialized antigen-presenting cells. This approach has been evaluated in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open label trial, 119 adults were randomly assigned to a conventional intramuscular injection or 40 percent of the usual dose (6 versus 15 mcg of hemagglutinin per strain) administered intradermally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/94\">",
"       94",
"      </a>",
"      ]. In comparison with the full-dose intramuscular injections, intradermal injections of the reduced dose resulted in similar antibody responses among persons 18 to 60 years of age, but not among those over the age of 60 years.",
"     </li>",
"     <li>",
"      A similar study evaluated the immunogenicity of a conventional intramuscular injection or 20 percent of the usual dose (3 mcg of hemagglutinin per strain) administered intradermally in healthy adults between the ages of 18 and 40 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/95\">",
"       95",
"      </a>",
"      ]. The rates of seroprotection were high and similar in the two groups (84 to 100 percent for the different strains).",
"     </li>",
"     <li>",
"      In a trial that included adults 65 years or older, there were no differences in immunogenicity between reduced dose (60 percent) intradermal administration and intramuscular administration at the reduced or full dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a trial of adults over age 60, those who received the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    using an intradermal microinjection system had higher antibody titers, seroprotection rates, and seroconversion rates compared with those who were vaccinated using routine intramuscular administration of the same dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2155317702\">",
"    <span class=\"h3\">",
"     Dual influenza and pneumococcal vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no randomized trials that have studied the effects of both vaccines administered together, a cohort study has suggested that dual influenza and pneumococcal vaccination is superior to either vaccine alone for preventing complications in elderly adults with chronic illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/98\">",
"     98",
"    </a>",
"    ]. In adults &ge;65 years of age with chronic illnesses, dual vaccination with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    and the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    resulted in lower rates of death (hazard ratio [HR] 0.65, 95% CI 0.55-0.77), pneumonia (HR 0.57, 95% CI 0.51-0.64), ischemic stroke (HR 0.67, 95% CI 0.54-0.83), and acute myocardial infarction (HR 0.52, 95% CI 0.38-0.71) compared with unvaccinated individuals. Dual vaccination also resulted in fewer coronary (HR 0.59, 95%CI, 0.44-0.79) and intensive care unit admissions (HR 0.45, 95% CI 0.22-0.94) compared with unvaccinated individuals.",
"   </p>",
"   <p>",
"    Pneumococcal vaccination is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination of a population may also be undertaken to protect their contacts. The underpinning for this approach is the concept of \"herd immunity,\" whereby the benefits of immunization may be passed indirectly to vulnerable populations by vaccinating those who may serve as vehicles for disease transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Household contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best data on the effect of influenza vaccination on household contacts come from studies in children, which are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H14#H14\">",
"     \"Seasonal influenza vaccination in children\", section on 'Herd immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of the key findings are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LAIV was given to 47 percent of students compared with no intervention in demographically similar elementary schools in four states [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/99\">",
"       99",
"      </a>",
"      ]. The primary objective of the study was to assess the effect of a school-based vaccination program on the households of children attending the schools. During a predicted week of peak influenza activity, all households with children in intervention and control schools were surveyed regarding influenza-like illness during the previous seven days. There were modest but significant reductions in the numbers of symptoms of respiratory illness and visits to clinicians among adults and children in the intervention households compared with control households. Absenteeism from elementary school and the number of workdays missed by adults were also significantly reduced.",
"     </li>",
"     <li>",
"      Inactivated vaccine was administered to offspring of military personnel attending daycare centers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/100\">",
"       100",
"      </a>",
"      ]. Unvaccinated household contacts of vaccinated children had 42 percent fewer febrile respiratory illnesses than unvaccinated household contacts of unvaccinated children; the degree of protection was greater (80 percent reduction) among school-aged household contacts who also had a 70 percent reduction in school days missed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Healthcare workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza vaccination of healthcare personnel in long term care facilities also improves patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/101\">",
"     101",
"    </a>",
"    ]. In a parallel group study, healthcare workers in long term care facilities were offered or not offered influenza vaccination; the rate of vaccination was 51 and 5 percent in the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/37\">",
"     37",
"    </a>",
"    ]. The uncorrected rate of patient mortality over six months in the winter of 1996-1997 was significantly lower in the vaccine hospitals (14 versus 22 percent). A similar reduction in patient mortality (10 versus 17 percent) was noted in another study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been concern that LAIV use in healthcare professionals could lead to secondary infections in patients. However, the risk is probably low since the vaccine recipient must shed the attenuated vaccine virus in sufficient quantities to result in transmission and, once acquired, the attenuated virus must revert to wild type to produce disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/102\">",
"     102",
"    </a>",
"    ]. Influenza vaccination in healthcare workers is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13322?source=see_link&amp;anchor=H8#H8\">",
"     \"Immunizations for healthcare providers\", section on 'Influenza vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59638617\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the cost-effectiveness of influenza vaccine in adults, including the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/103-107\">",
"     103-107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large study of healthy adults during two consecutive influenza seasons, the estimated net societal cost compared with no vaccination was $11.17 per person when the vaccine and predominant circulating viruses were well matched compared with $65.59 when the vaccine virus differed from the predominant circulating viruses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since vaccine efficacy varies from year to year, another analysis incorporated ten years of influenza surveillance data from the WHO in an attempt to determine cost-effectiveness of vaccine in healthy adults compared to treatment or no intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/106\">",
"       106",
"      </a>",
"      ]. On average, the cost-effectiveness of vaccination compared favorably with other commonly accepted interventions.",
"     </li>",
"     <li>",
"      A cost-benefit has also been demonstrated in high-risk elderly patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/107\">",
"       107",
"      </a>",
"      ]. Although there was a small net cost for vaccinating elderly patients not at high risk, it was thought that indirect benefits, such as prevention of suffering and lost wages, would compensate for the cost.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Inactivated vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inactivated influenza vaccines are generally well-tolerated, with the most common side effect being arm soreness at the injection site (in 64 percent of vaccine recipients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/108\">",
"     108",
"    </a>",
"    ]. In clinical trials, serious adverse events have been reported in fewer than 1 percent of vaccinated individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33\">",
"     33",
"    </a>",
"    ]. A slightly increased risk of Guillain-Barr&eacute; syndrome (GBS) has been associated with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    during certain influenza seasons, but this added risk appears to be substantially less than the overall health risk posed by naturally occurring influenza. This topic is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Influenza vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediate IgE-mediated hypersensitivity reactions have been reported rarely following influenza vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33\">",
"     33",
"    </a>",
"    ]. Oculorespiratory syndrome, an acute self-limited reaction, was first described during the 2000-2001 influenza season in Canada and has been reported occasionally within 24 hours of administration of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33,109\">",
"     33,109",
"    </a>",
"    ]. It is typically mild and is characterized by bilateral conjunctivitis, facial edema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory symptoms (eg, cough, wheezing). It is not thought to be IgE-mediated and a causal link to influenza vaccination has not been established. However, after changes to the manufacturing process to the vaccine formulation associated with oculorespiratory syndrome, the incidence dropped substantially.",
"   </p>",
"   <p>",
"    During the first year of post-marketing surveillance of the high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (Fluzone high dose), a greater proportion of gastrointestinal complaints (especially vomiting) was reported to the Vaccine Adverse Event Reporting System among recipients of the high-dose vaccine than among recipients of the standard dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Intranasal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The live-attenuated influenza vaccine (LAIV) is generally well-tolerated, with the most common side effects in adults being rhinorrhea, nasal congestion, headache, and sore throat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Out of 2.5 million people who received LAIV, the following serious adverse events have been reported to the Vaccine Adverse Event Reporting System (VAERS): possible anaphylaxis (seven), Guillain-Barr&eacute; syndrome (two), Bell's palsy (one), and asthma exacerbation among individuals with a history of asthma (eight) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza vaccination is contraindicated in patients who have had a severe allergic reaction (eg, anaphylaxis) to an influenza vaccine or its components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with egg allergy, we recommend an age-appropriate formulation of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    that was not produced in eggs (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"mobipreview.htm?41/31/42494\">",
"     table 2",
"    </a>",
"    ). If an egg-free vaccine is not available, an inactivated influenza vaccine produced in eggs can be used with some precautions. (See",
"    <a class=\"local\" href=\"#H775053590\">",
"     'Choice of vaccine formulation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"     \"Influenza vaccination in individuals with egg allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It seems prudent to withhold influenza immunization from individuals who developed Guillain-Barr&eacute; syndrome within six weeks after a previous influenza immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Influenza vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The live-attenuated intranasal vaccine should",
"    <strong>",
"     not",
"    </strong>",
"    be given to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9,33,36\">",
"     9,33,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunocompromised patients",
"     </li>",
"     <li>",
"      Patients with chronic cardiovascular, pulmonary (eg, asthma), or metabolic diseases (eg, diabetes or renal insufficiency)",
"     </li>",
"     <li>",
"      Persons who developed Guillain-Barr&eacute; syndrome within six weeks after a previous influenza immunization",
"     </li>",
"     <li>",
"      Pregnant women",
"     </li>",
"     <li>",
"      Persons with a history of egg allergy (because its safety in such patients has not been evaluated) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link&amp;anchor=H9#H9\">",
"       \"Influenza vaccination in individuals with egg allergy\", section on 'Options for testing and administration'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LAIV is not recommended for household members and healthcare professionals with close contact with severely immunocompromised persons (eg, transplant recipients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/114\">",
"     114",
"    </a>",
"    ]. It may be given to other healthcare providers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13322?source=see_link&amp;anchor=H8#H8\">",
"     \"Immunizations for healthcare providers\", section on 'Influenza vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Receipt of antivirals with activity against influenza virus (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    ) should be avoided for 48 hours before vaccination and for 14 days after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL AND ALTERNATIVE APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important drawbacks of traditional influenza vaccines include the need to design new vaccines each year to match circulating strains and the fact that the production process takes several months when embryonated eggs are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Alternative production methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;New influenza vaccines have been developed that do not use embryonated eggs as a vehicle for production. Non-egg based methods are attractive because they are less laborious, have a shorter production time, and do not depend on a supply of eggs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/26,55,115\">",
"     26,55,115",
"    </a>",
"    ]. Furthermore, vaccines made without eggs can be used in individuals who are allergic to eggs.",
"   </p>",
"   <p>",
"    Mammalian cell line-based vaccines also preserve the structure of the antibody-combining sites on the hemagglutinin antigen (HA), unlike egg-adapted influenza viruses; the preservation of the HA may result in more robust antibody responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/116\">",
"     116",
"    </a>",
"    ]. Cell-based vaccines may also induce broader immune responses, which might provide better protection against variant strains. Mammalian cells are also more permissive of influenza virus replication; certain influenza viruses, such as avian H5N1 viruses, do not replicate well in eggs.",
"   </p>",
"   <p>",
"    There has also been interest in a modified vaccinia Ankara (MVA) vector-based influenza vaccine because it induces an influenza virus-specific T cell response. In a small study, an MVA vector-based vaccine was safe and immunogenic in healthy individuals, and appeared to reduce the incidence of influenza infection following an intranasal challenge compared with unvaccinated individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/117\">",
"     117",
"    </a>",
"    ]. Among vaccinees who developed influenza infection, influenza symptoms were less pronounced and the duration of viral shedding was shorter than in unvaccinated individuals.",
"   </p>",
"   <p>",
"    <br/>",
"    Additional vaccines that are being evaluated employ other viral vectors (eg, vaccinia virus, adenoviruses, vesicular stomatitis virus,) or utilize virus-like particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/26\">",
"     26",
"    </a>",
"    ]. A vaccine that uses recombinant DNA technology and a baculovirus expression system to produce virus-like particles (Flublok) has been approved by the US Food and Drug Administration (FDA). (See",
"    <a class=\"local\" href=\"#H692172\">",
"     'Recombinant hemagglutinin vaccine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4445192\">",
"    <span class=\"h2\">",
"     Universal vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing research is focused on developing a universal vaccine that would elicit protective antibodies directed against conserved viral proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/26,118-123\">",
"     26,118-123",
"    </a>",
"    ]. Such a vaccine would provide protection against drifting influenza strains, as well as against newly emerging pandemic strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, a universal vaccine might also decrease the emergence of viral escape mutants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/118\">",
"     118",
"    </a>",
"    ]. Promising targets include the highly conserved external domain of the influenza matrix 2 protein and conserved epitopes from the influenza nucleoprotein, matrix 1 protein, and hemagglutinin protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most influenza vaccines have been designed to elicit a humoral immune response, in a phase I clinical trial, a Modified Vaccinia virus Ankara (MVA) vector that encodes the influenza nucleoprotein and matrix 1 protein boosted T cell responses, particularly CD8+ T cell responses, to all influenza A subtypes in healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/124\">",
"     124",
"    </a>",
"    ]. Such a vaccine has the benefit of being directed at epitopes within the conserved internal proteins of influenza viruses rather than at the highly variable surface proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/125\">",
"     125",
"    </a>",
"    ]. However, a potential drawback is that cytotoxic T cell immunity to influenza viruses may be short-lived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most neutralizing antibody responses in individuals who were infected with the H1N1 influenza A strain that caused the 2009-2010 pandemic were broadly cross-reactive against epitopes in the hemagglutinin stalk and head domain of multiple influenza strains, suggesting that a universal influenza vaccine might be developed using such immunogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78880699\">",
"    <span class=\"h2\">",
"     Reduced dose vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine shortages have occurred in some seasons. One approach to address this involves giving a reduced dose of vaccine in order to expand the available supply. In a trial of half versus full dose trivalent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    among healthy individuals who had previously been vaccinated, both doses led to equivalent protective hemagglutination titers (&ge;1:40) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/8/37002/abstract/127\">",
"     127",
"    </a>",
"    ]. However, geometric mean titers (GMTs) were slightly lower for all vaccine strains among those who received the reduced dose. Among women 18 to 49 years of age who received the half dose vaccine, titers were equal or higher than in men who received the full dose vaccine. Some subjects 50 to 64 years of age who received the half dose vaccine had GMTs that were unacceptably low. These findings suggest that in the presence of a vaccine shortage, administering half dose vaccine to targeted individuals (healthy women between the ages of 18 to 49 who have been vaccinated in previous years) might be an effective strategy.",
"   </p>",
"   <p>",
"    Using a reduced dose of vaccine by the intradermal route has also been evaluated in several studies, as discussed above. (See",
"    <a class=\"local\" href=\"#H385648\">",
"     'Intradermal delivery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=see_link\">",
"       \"Patient information: Flu (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"       \"Patient information: Vaccines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=see_link\">",
"       \"Patient information: Vaccines and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"       \"Patient information: Influenza prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"       \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/7/17522?source=see_link\">",
"       \"Patient information: Vaccination during pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304508\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza is an acute respiratory illness caused by influenza A or B viruses. It occurs in outbreaks and epidemics nearly every year, mainly during the winter season in temperate climates (",
"      <a class=\"graphic graphic_figure graphicRef60877 \" href=\"mobipreview.htm?12/3/12349\">",
"       figure 1",
"      </a>",
"      ). Influenza virus is remarkable for its high rate of mutation; this viral evolution compromises the ability of the immune system to protect against new viral variants. As a consequence, new vaccines are produced each year to match the vaccine with the new circulating viruses. Annual influenza vaccination is an important public health measure for preventing influenza infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Antigenic composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several influenza vaccines are licensed for use in the United States, including inactivated influenza vaccines, which are administered intramuscularly or intradermally, and a live-attenuated influenza vaccine, which is administered intranasally (",
"      <a class=\"graphic graphic_table graphicRef60449 \" href=\"mobipreview.htm?3/34/3630\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef79474 \" href=\"mobipreview.htm?41/31/42494\">",
"       table 2",
"      </a>",
"      ). The protection provided by influenza vaccines is based upon induction of virus-neutralizing antibodies, mainly directed against the viral hemagglutinin. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Vaccine formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In 2010, the United States Advisory Committee on Immunization Practices (ACIP) expanded the recommendation for influenza vaccination to include all individuals six months of age and older. High-risk individuals, their close contacts, and healthcare workers should remain high priority populations in vaccination campaigns (",
"      <a class=\"graphic graphic_table graphicRef79334 \" href=\"mobipreview.htm?28/14/28908\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H775052810\">",
"       'Schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A single dose of an influenza vaccine should be administered to adults annually and offered as soon as the vaccine becomes available, ideally by October in the northern hemisphere and May in the southern hemisphere. Annual immunization is necessary even if the previous year's vaccine contained one or more of the antigens to be administered, because immunity declines during the year following vaccination. (See",
"      <a class=\"local\" href=\"#H775052810\">",
"       'Schedule'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H775055218\">",
"       'Need for annual vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of vaccine formulation depends upon several factors, including age, comorbidities, pregnancy, and risk of adverse reactions (",
"      <a class=\"graphic graphic_table graphicRef60449 \" href=\"mobipreview.htm?3/34/3630\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef79474 \" href=\"mobipreview.htm?41/31/42494\">",
"       table 2",
"      </a>",
"      ). For healthy non-pregnant adults up to 49 years of age, either an inactivated vaccine or the live-attenuated influenza vaccine (LAIV) may be used. For all individuals &ge;50 years of age and for individuals with a contraindication to receiving LAIV (eg, immunocompromise; chronic cardiovascular, pulmonary, or metabolic disease; pregnancy; egg allergy), an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      is recommended. Certain individuals may receive a high-dose inactivated influenza vaccine (Fluzone high dose) or an intradermal formulation of the inactivated influenza vaccine (Fluzone intradermal). (See",
"      <a class=\"local\" href=\"#H775053590\">",
"       'Choice of vaccine formulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults with egg allergy, we recommend a trivalent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      that was not produced in eggs (",
"      <a class=\"graphic graphic_table graphicRef79474 \" href=\"mobipreview.htm?41/31/42494\">",
"       table 2",
"      </a>",
"      ). For individuals aged 18 to 49 years, either the vaccine produced in cultured mammalian cells (Flucelvax) or the vaccine produced using recombinant",
"      <span class=\"nowrap\">",
"       DNA/baculovirus",
"      </span>",
"      technology (Flublok) may be used. For individuals &gt;49 years of age, Flucelvax should be used. Flucelvax is available for the 2012-2013 influenza season, while Flublok may only be available in limited quantities towards the end of the 2012-2013 influenza season. If an egg-free vaccine is not available, an inactivated influenza vaccine produced in eggs can be used with some precautions. The LAIV is",
"      <strong>",
"       not",
"      </strong>",
"      recommended in patients with egg allergy. (See",
"      <a class=\"local\" href=\"#H775053590\">",
"       'Choice of vaccine formulation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"       \"Influenza vaccination in individuals with egg allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because influenza vaccines produced in eggs take approximately nine months to manufacture, they necessarily contain antigens from strains that circulated during the previous year. The protective efficacy of the vaccine is largely determined by the relationship (closeness of \"fit\" or \"match\") between the strains in the vaccine and viruses that circulate in the outbreak. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Immunogenicity, efficacy, and safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although many studies evaluating the efficacy of influenza vaccines in healthy adults have been published and efficacy is often estimated to be between 70 and 90 percent, vaccine efficacy in adults in a 2012 meta-analysis was only 59 percent. The United States Centers for Disease Control and Prevention estimates that the overall effectiveness of 2012-2013 seasonal influenza vaccine in preventing medically-attended influenza infections for all age groups is 56 percent, but only 9 percent against H3N2 influenza A viruses among individuals &ge;65 years of age. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Immunogenicity, efficacy, and safety'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H205840196\">",
"       'Effectiveness for the 2012-2013 season'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/1\">",
"      Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N Engl J Med 2008; 359:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/2\">",
"      Talbot TR, Talbot HK. Influenza prevention update: examining common arguments against influenza vaccination. JAMA 2013; 309:881.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC reports cases 18-29 of H3N2v virus infection; continues to recommend interim precautions when interacting with pigs. file://www.cdc.gov/flu/spotlights/h3n2v_us_cases.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/4\">",
"      Centers for Disease Control and Prevention. Evaluation of rapid influenza diagnostic tests for influenza A (H3N2)v virus and updated case count &mdash; United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61 (Early Release):1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Case count: detected U.S. human infections with H3N2v by state since August 2011 file://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm (Accessed on September 21, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Interim information for clinicians about human infections with H3N2v virus. file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm (Accessed on August 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/7\">",
"      Skowronski DM, Janjua NZ, De Serres G, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis 2012; 206:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/8\">",
"      Kilbourne ED. Influenza immunity: new insights from old studies. J Infect Dis 2006; 193:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Seasonal influenza vaccine safety: a summary for clinicians. file://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm (Accessed on March 14, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration News Release. FDA approves first quadrivalent vaccine to prevent seasonal influenza. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm (Accessed on May 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/12\">",
"      Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs 2012; 72:2177.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Approval letter - Fluarix quadrivalent. file://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm332484.htm (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     GlaxoSmithKline. FDA Approves GlaxoSmithKline&rsquo;s four-strain seasonal influenza vaccine for use in the US. file://www.gsk.com/media/press-releases/2012/FDA-pproves-GlaxoSmithKline-four-strain-seasonal-influenza-vaccine-for-use-in-the-US.html (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. file://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf (Accessed on February 25, 2012).",
"    </li>",
"    <li>",
"     World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013 southern hemisphere influenza season. file://www.who.int/influenza/vaccines/virus/recommendations/2013_south/en/index.html (Accessed on February 06, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013-14 northern hemisphere influenza season. file://www.who.int/influenza/vaccines/virus/recommendations/2013_14_north/en/index.html (Accessed on March 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/18\">",
"      Hensley SE, Das SR, Bailey AL, et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009; 326:734.",
"     </a>",
"    </li>",
"    <li>",
"     FluMist 60,000-patient phase IV safety study to be conducted with Kaiser. In: \"The Pink Sheet\" F-D-C Reports, Chevy Chase, MD, June 23, 2003, p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged &gt;or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:485.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. May 9, 2011. Approval Letter - Fluzone Intradermal. file://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm255160.htm (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     Sanofi Pasteur Press Release. FDA Licenses Sanofi Pasteur&rsquo;s New Influenza Vaccine Delivered by Intradermal Microinjection. file://multivu.prnewswire.com/mnr/sanofipasteur/49833/ (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     FDA news release. FDA approves new seasonal influenza vaccine made using novel technology file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm (Accessed on January 17, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/26\">",
"      Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010; 363:2036.",
"     </a>",
"    </li>",
"    <li>",
"     CDC's Advisory Committee on Immunization Practices (ACIP) recommends universal annual influenza vaccination. file://www.cdc.gov/media/pressrel/2010/r100224.htm (Accessed on May 16, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. Recommended composition of influenza virus vaccines for use in the 2010 southern hemisphere influenza season. file://www.who.int/csr/disease/influenza/recommendations2010south/en/index.html (Accessed on October 20, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/29\">",
"      Moura FE. Influenza in the tropics. Curr Opin Infect Dis 2010; 23:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/30\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     Medscape news. FDA okays novel flu vaccine made without eggs, viruses. file://www.medscape.com/viewarticle/777773?src=nl_newsalert (Accessed on January 18, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/32\">",
"      Sibley WA, Bamford CR, Laguna JF. Influenza vaccination in patients with multiple sclerosis. JAMA 1976; 236:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/33\">",
"      Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/34\">",
"      Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/35\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Who should get vaccinated against influenza. file://www.cdc.gov/flu/protect/whoshouldvax.htm (Accessed on August 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/37\">",
"      Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000; 355:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/38\">",
"      Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/39\">",
"      Thomas RE, Jefferson TO, Demicheli V, Rivetti D. Influenza vaccination for health-care workers who work with elderly people in institutions: a systematic review. Lancet Infect Dis 2006; 6:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/40\">",
"      Pearson ML, Bridges CB, Harper SA, et al. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/41\">",
"      Finch M. Point: mandatory influenza vaccination for all heath care workers? Seven reasons to say \"no\". Clin Infect Dis 2006; 42:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/42\">",
"      Backer H. Counterpoint: in favor of mandatory influenza vaccine for all health care workers. Clin Infect Dis 2006; 42:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/43\">",
"      Babcock HM, Gemeinhart N, Jones M, et al. Mandatory influenza vaccination of health care workers: translating policy to practice. Clin Infect Dis 2010; 50:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/44\">",
"      Miller BL, Ahmed F, Lindley MC, Wortley PM. Institutional requirements for influenza vaccination of healthcare personnel: results from a nationally representative survey of acute care hospitals--United States, 2011. Clin Infect Dis 2011; 53:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/45\">",
"      Nair H, Holmes A, Rudan I, Car J. Influenza vaccination in healthcare professionals. BMJ 2012; 344:e2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/46\">",
"      Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet 1995; 346:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/47\">",
"      Voordouw AC, Sturkenboom MC, Dieleman JP, et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA 2004; 292:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/48\">",
"      Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/49\">",
"      Kwong JC, Maaten S, Upshur RE, et al. The effect of universal influenza immunization on antibiotic prescriptions: an ecological study. Clin Infect Dis 2009; 49:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep 2013; 62:119.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research &amp; Policy. The compelling need for game-changing influenza vaccines an analysis of the influenza vaccine enterprise and recommendations for the future. file://www.cidrap.umn.edu/cidrap/files/80/ccivi%20report.pdf (Accessed on January 10, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/52\">",
"      Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/53\">",
"      Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; :CD001269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/54\">",
"      Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/55\">",
"      Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/56\">",
"      Reisinger KS, Block SL, Izu A, et al. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/57\">",
"      Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture&ndash;derived and egg���derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/58\">",
"      Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/59\">",
"      Ehrlich HJ, Singer J, Berezuk G, et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis 2012; 54:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/60\">",
"      Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007; 297:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/61\">",
"      Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok&reg;) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/62\">",
"      Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/63\">",
"      Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/64\">",
"      Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/65\">",
"      Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/66\">",
"      Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009; 301:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/67\">",
"      Phillips CJ, Woolpert T, Sevick C, et al. Comparison of the effectiveness of trivalent inactivated influenza vaccine and live, attenuated influenza vaccine in preventing influenza-like illness among US military service members, 2006-2009. Clin Infect Dis 2013; 56:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/68\">",
"      Fukuda K, Kieny MP. Different approaches to influenza vaccination. N Engl J Med 2006; 355:2586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/69\">",
"      Sprenger MJ, Mulder PG, Beyer WE, et al. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993; 22:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/70\">",
"      Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/71\">",
"      Edmondson WP Jr, Rothenberg R, White PW, Gwaltney JM Jr. A comparison of subcutaneous, nasal, and combined influenza vaccination. II. Protection against natural challenge. Am J Epidemiol 1971; 93:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/72\">",
"      Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000; 19:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/73\">",
"      Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/74\">",
"      Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/75\">",
"      Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/76\">",
"      Mangtani P, Cumberland P, Hodgson CR, et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004; 190:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/77\">",
"      Armstrong BG, Mangtani P, Fletcher A, et al. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ 2004; 329:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/78\">",
"      Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004; 39:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/79\">",
"      Jackson ML, Nelson JC, Weiss NS, et al. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008; 372:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/80\">",
"      Talbot HK, Griffin MR, Chen Q, et al. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011; 203:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/81\">",
"      Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002; 35:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/82\">",
"      Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/83\">",
"      Herzog NS, Bratzler DW, Houck PM, et al. Effects of previous influenza vaccination on subsequent readmission and mortality in elderly patients hospitalized with pneumonia. Am J Med 2003; 115:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/84\">",
"      Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; :CD004876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/85\">",
"      Wong K, Campitelli MA, Stukel TA, Kwong JC. Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med 2012; 172:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/86\">",
"      Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/87\">",
"      Groenwold RH, Hoes AW, Hak E. Impact of influenza vaccination on mortality risk among the elderly. Eur Respir J 2009; 34:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/88\">",
"      Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside \"flu\" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/89\">",
"      Jackson LA. Benefits of examining influenza vaccine associations outside of influenza season. Am J Respir Crit Care Med 2008; 178:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/90\">",
"      Brookhart MA, McGrath L. The influenza vaccine in elderly persons: a shot in the dark? Arch Intern Med 2012; 172:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/91\">",
"      Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/92\">",
"      Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/93\">",
"      Keitel WA, Atmar RL, Nino D, et al. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis 2008; 198:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/94\">",
"      Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/95\">",
"      Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/96\">",
"      Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis 2010; 50:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/97\">",
"      Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/98\">",
"      Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 2010; 51:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/99\">",
"      King JC Jr, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006; 355:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/100\">",
"      Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000; 284:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/101\">",
"      Thomas RE, Jefferson T, Demicheli V, Rivetti D. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2006; :CD005187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/102\">",
"      Cosgrove SE, Fishman NO, Talbot TR, et al. Strategies for use of a limited influenza vaccine supply. JAMA 2005; 293:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/103\">",
"      Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/104\">",
"      Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001; 33:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/105\">",
"      Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/106\">",
"      Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/107\">",
"      Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/108\">",
"      Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med 1996; 156:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/109\">",
"      Skowronski DM, Strauss B, De Serres G, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis 2003; 36:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/110\">",
"      Moro PL, Arana J, Cano M, et al. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010. Clin Infect Dis 2012; 54:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/111\">",
"      Harper SA, Fukuda K, Cox NJ, et al. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/112\">",
"      Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005; 294:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/113\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/114\">",
"      Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/115\">",
"      Neuzil KM, Bright RA. Influenza vaccine manufacture: keeping up with change. J Infect Dis 2009; 200:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/116\">",
"      Glezen WP. Cell-culture-derived influenza vaccine production. Lancet 2011; 377:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/117\">",
"      Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012; 55:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/118\">",
"      Gerhard W, Mozdzanowska K, Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006; 12:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/119\">",
"      Wei CJ, Boyington JC, McTamney PM, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/120\">",
"      Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/121\">",
"      Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/122\">",
"      Russell CJ. Stalking influenza diversity with a universal antibody. N Engl J Med 2011; 365:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/123\">",
"      Miller MS, Tsibane T, Krammer F, et al. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 2013; 207:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/124\">",
"      Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/125\">",
"      Hambleton S. Editorial commentary: a better grip: T cells strengthen our hand against influenza. Clin Infect Dis 2011; 52:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/126\">",
"      Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/8/37002/abstract/127\">",
"      Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008; 168:2405.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7007 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_37002=[""].join("\n");
var outline_f36_8_37002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1304508\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H775063374\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Influenza activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antigenic composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vaccine formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H775065130\">",
"      Vaccine supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184898325\">",
"      APPROACH TO IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H775052687\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H775052810\">",
"      Schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H775053590\">",
"      Choice of vaccine formulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H775073919\">",
"      Adminstration with other vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H775072460\">",
"      High-priority groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H775072578\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H775072633\">",
"      - Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H775072688\">",
"      - Healthcare workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H775055218\">",
"      Need for annual vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMMUNOGENICITY, EFFICACY, AND SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H205840196\">",
"      Effectiveness for the 2012-2013 season",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Healthy adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Trivalent inactivated vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H861848209\">",
"      - Cell-based inactivated vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H692172\">",
"      - Recombinant hemagglutinin vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Live-attenuated vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Comparisons of inactivated and live-attenuated vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H78890919\">",
"      - Standard-dose inactivated vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H78890862\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Effect on mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H78890805\">",
"      Waning of antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H384358\">",
"      - High-dose vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H385648\">",
"      - Intradermal delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2155317702\">",
"      - Dual influenza and pneumococcal vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Contacts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Household contacts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Healthcare workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59638617\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Inactivated vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Intranasal vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      INVESTIGATIONAL AND ALTERNATIVE APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Alternative production methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4445192\">",
"      Universal vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78880699\">",
"      Reduced dose vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304508\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7007\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7007|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/3/12349\" title=\"figure 1\">",
"      Peak influenza activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7007|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/34/3630\" title=\"table 1\">",
"      Comparison IIV LAIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/31/42494\" title=\"table 2\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/14/28908\" title=\"table 3\">",
"      Priority groups for flu vaccine if supply limited",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/50/33579\" title=\"table 4\">",
"      Groups at high risk for influenza complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=related_link\">",
"      Avian influenza vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13322?source=related_link\">",
"      Immunizations for healthcare providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/7/17522?source=related_link\">",
"      Patient information: Vaccination during pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=related_link\">",
"      Patient information: Vaccines and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_8_37003="Radiopaque toxins";
var content_f36_8_37003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents possibly radiopaque on plain x-ray",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"centered\" rowspan=\"3\">",
"        <strong>",
"         C",
"        </strong>",
"       </td>",
"       <td>",
"        Chlorinated hydrocarbons (eg, chloral hydrate, carbon tetrachloride)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium salts (eg, calcium carbonate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crack vials",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\">",
"        <strong>",
"         H",
"        </strong>",
"       </td>",
"       <td>",
"        Heavy metals (eg, iron, arsenic, mercury, thallium, lead)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\">",
"        <strong>",
"         I",
"        </strong>",
"       </td>",
"       <td>",
"        Iodinated compounds (eg, thyroxine)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\" rowspan=\"4\">",
"        <strong>",
"         P",
"        </strong>",
"       </td>",
"       <td>",
"        Psychotropics (eg, phenothiazines, lithium, cyclic antidepressants)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Packets of drugs (eg, cocaine and heroin \"body packers\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Play-Doh",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium salts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\">",
"        <strong>",
"         E",
"        </strong>",
"       </td>",
"       <td>",
"        Enteric-coated tablets (eg, aspirin)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\" rowspan=\"3\">",
"        <strong>",
"         S",
"        </strong>",
"       </td>",
"       <td>",
"        Salicylates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium salts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sustained-release preparations",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_37003=[""].join("\n");
var outline_f36_8_37003=null;
var title_f36_8_37004="Severe drug eruptions ddx";
var content_f36_8_37004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and laboratory features of severe drug eruptions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rash morphology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Localization",
"       </td>",
"       <td class=\"subtitle1\">",
"        Timing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Internal organ involvement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory findings",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        DHS/DRESS",
"       </td>",
"       <td>",
"        <p>",
"         Maculopapular exanthem",
"        </p>",
"        <p>",
"         Erythroderma",
"        </p>",
"        Facial edema",
"       </td>",
"       <td>",
"        <p>",
"         Generalized",
"        </p>",
"        Mucosal involvement infrequent",
"       </td>",
"       <td>",
"        &gt;14 days",
"       </td>",
"       <td>",
"        <p>",
"         Lymphadenopathy",
"        </p>",
"        <p>",
"         Hepatitis",
"        </p>",
"        <p>",
"         Pneumonitis",
"        </p>",
"        Nephritis",
"       </td>",
"       <td>",
"        <p>",
"         Fever",
"        </p>",
"        <p>",
"         Malaise",
"        </p>",
"        Fatigue",
"       </td>",
"       <td>",
"        <p>",
"         Eosinophilia, atypical lymphocytes",
"        </p>",
"        Abnormal liver, renal function tests",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        AGEP",
"       </td>",
"       <td>",
"        <p>",
"         Widespread erythema",
"        </p>",
"        <p>",
"         Erythroderma",
"        </p>",
"        Pustules (small, numerous)",
"       </td>",
"       <td>",
"        <p>",
"         Generalized, rarely flexural",
"        </p>",
"        Mucosal involvement rare",
"       </td>",
"       <td>",
"        &lt;3 days",
"       </td>",
"       <td>",
"        Possible but rare",
"       </td>",
"       <td>",
"        High fever (&gt;38&deg;C)",
"       </td>",
"       <td>",
"        Leukocytosis with neutrophilia (&gt;7000/mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SJS/TEN",
"       </td>",
"       <td>",
"        <p>",
"         Dusky red, coalescent macular exanthem",
"        </p>",
"        <p>",
"         Atypical target lesions",
"        </p>",
"        <p>",
"         Bullous lesions",
"        </p>",
"        <p>",
"         Epidermal necrosis (&lt;10 percent in SJS, 10 to 30 percent in SJS/TEN, &gt;30 percent in TEN)",
"        </p>",
"        Nikolsky sign (ready removal of the epidermis with slight tangential pressure",
"       </td>",
"       <td>",
"        <p>",
"         Disseminated",
"        </p>",
"        Mucosal involvement nearly in all cases (stomatitis, conjunctivitis)",
"       </td>",
"       <td>",
"        4 to 21 days",
"       </td>",
"       <td>",
"        Pneumonitis",
"       </td>",
"       <td>",
"        <p>",
"         Fever",
"        </p>",
"        <p>",
"         Malaise",
"        </p>",
"        <p>",
"         Fatigue",
"        </p>",
"        <p>",
"         Sore throat",
"        </p>",
"        Dysphagia, photophobia",
"       </td>",
"       <td>",
"        <p>",
"         Lymphopenia",
"        </p>",
"        Epidermal necrosis on skin biopsy with full-thickness loss of epidermis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DHS/DRESS: drug hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms; AGEP: acute generalized exanthematous pustulosis; SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Scherer K, Bircher A. Adverse drug reactions and the skin--from trivial to fire signal. Internist (Berl) 2009; 50:171.",
"      </li>",
"      <li>",
"       Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am 2010; 94:711.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_37004=[""].join("\n");
var outline_f36_8_37004=null;
var title_f36_8_37005="SVT children algorithm";
var content_f36_8_37005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for differentiation of typical AVNRT and orthodromic AVRT in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 371px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AVNRT: atrioventricular nodal reentrant tachycardia; AVRT: atrioventricular reentrant tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Jaeggi, ET, Gilljam, T, Bauersfeld, U, et al. Am J Cardiol 2003; 91:1084.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_37005=[""].join("\n");
var outline_f36_8_37005=null;
var title_f36_8_37006="Sinus symptoms with migraine";
var content_f36_8_37006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Sinus symptoms are common in patients with migraine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 394px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this observational study of patients with a history of sinus headache and no previous history of migraine, sinus pain, pressure, and congestion commonly occurred in association with typical migraine features such as pulsing head pain, and sensitivity to activity, light, and sound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schreiber CP, Hutchinson S, Webster CJ, et al. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed \"sinus\" headache. Arch Intern Med 2004; 164:1769. Copyright &copy; 2004 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_37006=[""].join("\n");
var outline_f36_8_37006=null;
var title_f36_8_37007="Patellar tendon tear";
var content_f36_8_37007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patellar tendon tear and avulsion fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral radiograph of the knee demonstrates a high position of the patella (arrow) secondary to a torn patellar tendon. A small fragment of the inferior aspect of the patella (patellar avulsion fracture) is also noted (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_8_37007=[""].join("\n");
var outline_f36_8_37007=null;
